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CHAPTER I
INTRODUCTION
Anthracyclines, such as daunomycin and adriamycin have been the
subject of intense recent investigation.
been, partially

Many of these studies have

at least, motivated by the demonstrated effectiveness

of anthracyclines in the treatment of leukemias and other forms of
cancer.
The biological and pharmacological activities of these drugs
appear to be, at least in part, due to their ability to interact with
DNA.

Specifically, daunomycin and adriamycin can intercalate into DNA

and inactivate its template function essential for nucleic acid synthesis.
Recently, several structural analogs of these antineoplastic
agents have been synthesized and some of them were shown to be considerably more effective against experimental tumors than the parent compounds.
The majority of recent studies of these daunomycin derivatives have indicated that the increased effectiveness of these new drugs may relate to
their different modes of interaction with the target molecule, DNA.
Clearly the interaction between anthracyclines and the DNA
template may be expected to influence the mechanism by which these antibiotics inhibit nucleic acid synthesis.
is available in this area.

However, very little information

The goal of this research project is to study

the mechanism by which several structurally related anthracyclines inhibit the synthesis of RNA.
1

2

r.l.

Structures of Anthracycline Analogs:

Daunomycin (daunorubicin) is an antibiotic isolated from cultures of streptomyces peucetius (DiMarco et al., l964a).

This drug in-

hibits strongly the multiplication of bacterial and animal viruses and
exhibits a high cytotoxic activity against normal and neoplastic cells
(DiMarco et al., 1964b).

The active form of the drug was isolated as

crystalline hydrochloride with the empirical formula:

c27 H29 o10N•HC1.

The

structure of daunomycin has been shown to be a glycosidic antibiotic
constituted by a red, water insoluble, tetracyclic aglycone (daunomycinone,

c 21 H18 o

8

)

(Arcamone, et al., 1964a) linked to a reducing (posi-

tive Fehling, Tollens tests), water soluble amino-sugar (positive ElsonMorgan ninhydrin) named daunosamine or 2,3,6-trideoxy-3-amino-Llyxohexose (c H No ) (Arcamone et al., 1964b).
6 13 3
(0.2N

Mild acid hydrolysis

hydrochloric acid for 1 hr. at 90°C) can resolve the drug into its

two components (Arcamone et al., 1964).

The structure and absolute con-

figuration of daunomycin and its components are now known in detail
(Arcamone et al., 1968) and are presented in Figure la.
From the X-ray crystallographic studies of the N-bromoacetyl
derivative of daunomycin, the shape of the molecule in the solid state is
shown in Figure 2.

The cyclohexene ring or ring D is in the "half-chair"

conformation (Angiuli et al., 1971) and the C-9 is displaced from the
0

plane of the remaining five atoms by about 7 A and toward the C-9
hydroxyl.

A more detailed picture can be found in Figure 4A.

The six

membered daunosamine ring was found to be in the chair conformation oriented perpendicularly to the planar chromophore.
The physico-chemical characteristics of daunomycin show remarkable

3

Figure l.

Structures of anthracycline analogs:
(a) Daunomycin;

(b) 4-demethoxydaunomycin;

(c) carminomycin;

(d) aclacinomycin;

(e) marcellomycin;

(f) musettamycin.
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Figure 2.

Three-dimensional structure of N-bromoacetyldaunomycin

as indicated by X-ray analysis

7

8

similarities with those of the antibiotics classified as "Anthracyclines"
(Ollis et at., 1961) and therefore it is accepted as a member of the
anthracycline family (Zunino et al., 1972).
Adriamycin (14-hydroxydaunomycin) was obtained from cultures of
streptomyces peucetius var. caesius (Arcamone et al., 1969a).

This anti-

biotic gave, on acid hydrolysis, the aglycone, adriamycinone (14hydroxydaunomycinone), and the amino sugar daunosamine.

The structure

and absolute configuration of adriamycin were established on the basis of
chemical and spectroscopic evidence (Arcamone et al., 1969b) and are also
shown in Figure 1.
The structures of the rest of the anthracycline analogs studied
in this project are also shown in Figure 1 and they will be discussed
separately in a latter section.

9

I.2.

L 2 .1.

Pharmacological and Biological Properties of Daunomycin and Its
Analogs
Antibiotic Activity

While only weakly active against some gram-positive and gramnegative bacteria and fungi (DiMarco, 1967), daunomycin shows much
higher inhibitory activity against the multiplication of other bacteria
such as E. coli; although different strains of E. coli have different
susceptibilities (DiMarco et al., 1975).
Daunomycin was found to be active against the multiplication of
double-stranded DNA bacteriophage (e.g. T6) but not single-stranded DNA
bacteriophage (e.g. EC9 and 513)

(Calendi et al., 1966).

The interfe-

renee is not related to a direct inactivation of the phage particles or
an inhibition of their absorption to the bacterial cell (Parisi et al.,
1964).
The inhibitory effect of daunomycin was also demonstrated on
other double-stranded DNA viruses (e.g. Herpes simplex virus) when administered before or at the early stage of infection.

It is not effec-

tive after mature virions appear (DiMarco et al., 1968).
Daunomycin is ineffective against the replication of animal RNAviruses with the exception of Newcastle Disease Virus (NDV) providing
that the daunomycin-NOV mixtures are exposed to light (Verini et al.,
1968).
By evaluation of the number of mitotic figures (mitotic index,
MI) or of the proliferative activity of cells it was shown that daunomycin has a strong inhibiting effect on the in vitro growth of a number

10

of cells strains both normal and neoplastic (DiMarco et al., 1975).
cell damage induced by daunomycin is mainly nuclear, such as changes in
the appearance of chromatin as well as the shape and size of the nucleoli.
The changes appear soon after daunomycin addition to the medium of cell
culture.

During mitosis, chromosomal damage, such as fragmentations and

mitotic aberrations can be observed by phase microscopy immediately after
a sufficient amount of daunomycin is added (DiMarco et al., 1964b).
Cytoplasmic changes, such as vacuolization, are moderate and occur only
after prolonged treatment with high doses.
induce significant alterations in

membranes

Adriamycin also was found to
characterized by altered

cellular agglutination ability and mitotic arrest (Murphree et at., 1976).
Daunomycin also has a strong inhibitory effect on experimental
tumor cells such as ascites tumor; solid tumors show a lesser susceptibility (DiMarco et al., 1970).

Adriamycin is more effective than daunomy-

cin in increasing survival time in animals bearing Ehrlich ascites tumors
(DiMarco et al., 1969) or Ll210 leukemia (Sandberg et al., 1970) and
exerts a high inhibitory effect on the growth of many other experimental
tumors (DiMarco et al., 1971).

It is under these experimental conditions

that the difference between the two antibiotics is particularly evident.

I.2.2.

Drug Distribution and Excretion

With the advantage of the fluorescence property of the anthracyclines, the distribution and excretion of daunomycin and adriamycin
have been studied in animals (Di Fronzo and Gambetta, 197la; Di Fonzo
et al., l97lb).

Both drugs are rapidly cleared from the blood stream

and fixed by body tissues and organs.

The two antibiotics do not appear

11
to cross the blood brain barrier.
As it is expected for drugs which interfere with nucleic acids
synthesis (see section I.2.6.), the tissues most susceptible to the two
antibiotics are rapidly proliferating such as intestinal mucosa, lymphoid
organs and bone marrow (DiMarco et al., 1975).
Both drugs are excreted slowly into urine and the bile, however,
adriamycin was found to be excreted much slower than daunomycin in rats
and mice (Yesair et al., 1971).

The calculated "concentration x time"

(C x t) in the case of adriamycin equivalents has been demonstrated in
all tissues to be several times greater than that found for daunomycin.

I. 2. 3.

Drug Metabolism

As indicated in the metabolic pathway depicted in Figure 3,
daunomycin is metabolized by a aldo-keto reductase, daunomycin reductase
(Bachur et al., 1971) to form daunorubicinol.

This reduced product is

not only the pricipal drug form excreted by human and animals (Cradock
et al., 1973: Bachur et al., 1974) but also retains significant cytotoxic
activity.
Daunomycin and daunorubicinol can also be further metabolized
by either reductive or hydrolytic glycosidases (Bachur et al., 1972) to
form aglycones which have low water but high lipid solubility.
lization of these aglycones can take place through
and 0-sulfation (Takanashi

e~

al., 1975).

Solubi-

0-~-glucuronidation

The conjugate products can

then be excreted through urine.

I.2.4.

Clinical Toxicity

The most frequent signs of toxicity caused in patients by both

12

Figure 3.
I.

Proposed pathway for human daunmycin metabolism

daunomycin; II, daunorubicinol; III, daunorubicinol aglycone;

IV, deoxydaunorubicin aglycone; V, deoxydaunorubicinol aglycone;
VI, demethyl deoxydaunorubicinol aglycone; VII, deoxydaunorubicinol
aglycone-13-0-~--glucuronide;

VIII, demethyl deoxydaunorubicinol

aglycone-4-0-sulfate; IX, demethyl deoxydaunorubicinol aglycone-4-0
~-glucuronide.
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daunomycin and adriamycin are stomatitis, alopecia, bone marrow depression, and gastrointestinal disturbances (Bernard et al., 1969).
nificant kidney damage has been reported.

No sig-

A peculiar toxic effect of

these drugs is a cardiopulmonary syndrome (Bonadonna et al., 1969) consisting of tachycardia, with or without arrhythmia, hypotension, gallop
rhythm, tachypnea, and congestive heart failure, not relieved by digitalis.

The mechanism of this effect has not been elucidated.

Cardiac

toxicity is more frequently observed when high doses (more than 25-30
mg/kg) are given, and in elderly patients (DiMarco et al., 1975).

When

an intermittent, rather than a daily dose schedule is used, cardiac
toxicity is rarely observed.

I.2.5.

Therapeutic Values

The main therapeutic indications of daunomycin and adriamycin
are leukemias, especially acute lymphocytic leukemia in children.

Be-

cause of the occurence of cardiac toxicity, the drugs are used, alone or
in combination with other antitumor agents, mainly for remission induction
and reinforcement dosing during remissions rather than for maintenance
therapy (DiMarco et al., 1975).

Both daunomycin and adriamycin are also

active on lymphomatous neoplasms (e.g. Hodgkin's disease lymphosarcoma,
reticular cell sarcoma) .
Daunomycin has little or no effect on solid tumors, whereas
adriamycin appears to be temporarily effective in a range of childhood
tumors such as Ewing's sarcoma, neublastoma, osteogenic sarcoma and some
anaplastic sarcomas (Bonadonna et al., 1970).

In adults, chemothera-

peutic effectiveness has been obtained in breast cancer, seminoma, ges-

15

tional choricocaricinoma and other soft tissue sarcomas, transitional
cell carcinomas of the bladder, and lung cancer.

I.2.6.

The Mode of Action of Daunomycin and Its Analogs

The fluorescence of daunomycin enables the investigation of the
events which occur after the cells are incubated with the drug.

It has

been shown that daunomycin penetrates the cell and fixes itself in the
nuclear structure (Calendi et al., 1965).

The radiochemical data have

confirmed that a large portion of daunomycin which enters the cell is
taken up by the nucleus (DiMarco et al., 1975).

In synchronized

cultured cells it has been shown that the up-take of the drug occurs
through the regenerative cycle, and reaches its maximum during DNA
replication (Silvestrini et al., 1970).
In cultures of mammalian cells, daunomycin strongly inhibits
adenine-s-c

14

incorporation into RNA (Rusconi et al., 1966).

This inter-

ference with the incorporation of labeled precursors into RNA is consistent with the findings that daunomycin inhibits in vitro DNA-dependent
RNA polymerase (DiMarco et al., 1965).

In cultured animal cells, RNA

synthesis in the nucleolus is particularly sensitive to the drug (Angiuli
et al., 1971).

Autoradiographic studies carried out in vitro cultures of

Hela cells (DiMarco et al., 1965; Crook et al., 1972) showed a higher
inhibition of ribosomal RNA synthesis than messenger RNA synthesis.

This

preferential inhibition of nucleolar RNA is described in more detail in
section I.2.8.1.
Inhibition of DNA synthesis by daunomycin has also been observed
by following the incorporation of

3

H-thymidine into nucleic acids

16

(Rusconi et al., 1969).

This inhibitory effect of daunomycin is correla-

ted with the interference of daunomycin with the activity of DNA-dependent
DNA polymerase (Hartman et al., 1964).
Studies have shown that when the daunomycin and the precursors
of nucleic acids synthesis are added to the cell cultures at the same
time, there are no significant differences in the relative inhibition of
precursors uptake into DNA or RNA (Rusconi et al., 1969).

Other auto-

radiographic studies have reported the influence of daunomycin on nucleic
acids synthesis during different phases of cell cycle (Silvestrini et
al., 1970).

The effect of daunomycin inhibition is more evident on DNA

synthesis which occurs in the late S phase, tentatively indentified with
heterochromatin duplication and on RNA synthesis which occurs in the
middle of G and in the G phases just before the mitotic peak (Simard,
1
2
1967).

The observation (Kim et al., 1968) that the lethal effect of

-- --

duanomycin on a synchronously dividing population of Hela cells is higher
inS phase than in G or G phase suggeststhat the accessibility of DNA
1
2
in chromosomal structures and repair processes may vary during the divisian cycle.

Since a strong binding of daunomycin to DNA occurs only with

double-stranded DNA (see section I.2.7.2.), one might assume that during
the process of replication the drug could find access to DNA, bind strongly and irreversibly damage the chromosomal structure to cause cell death.
In any event, the inhibition of these important metabolic events such as
nucleic acid synthesis can explain the arrest of cullular reproduction.
However, an immediate antimitotic activity of daunomycin (see section
I.2.1.) which seems to be unrelated to the inhibition of RNA of DNA
synthesis may indicate that the stiffening of DNA by the drug, which will
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be discussed in the following section, may contribute to the chromosomal
damage (Di Marco, 1967).

I.2.7.

The Mechanism of Action of Daunomycin

Substantial amount of evidence suggest that daunomycin interferes
with template activity by intercalating between the base pairs of the
double helical DNA.

I.2.7.l. Spectral Evidence for Drug Binding to DNA

Initially, studies on the interaction of daunomycin with DNA
(Calendi et al., 1965) revealed some physico-chemical changes upon formation of the daunomycin-DNA complex.
range with a maximum at 475 nm.

Daunomycin absorbs in the visible

Its ultraviolet absorption spectrum

shows two maxima at 233 nm and 255 nm.

Daunomycin also shows a typical

fluorescence spectrum with an emission at 580 nm when exicted at 485 nm.
When native or heat denatured DNA from various sources are added
to an aqueous solution of daunomycin the antibiotic shows:

(a) changes in

visible absorption spectrum (both hypochromic, lowering of the absorbance
at 475 nm, and bathochromic, shifting of its absorption maximum to 505
nm);

(b) changes in ultraviolet absorption spectrum (lowering of absor-

bance at 233 nm and 255 nm and shifting of the two absorption maxima to a
single maximum at 257 nm);

(c) reduction of antibiotic fluoresence (almost

complete disappearance of fluorescence)

(Calendi et al., 1965).

No such

changes are observed when nucleotides, nucleosides, or free based are
added to daunomycin solution.
Daunomycin aqueous solution is characterized by its red color.
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At alkaline pH (9.4-9.8), the drug changes its color to blue due to salt
formation of the compound (Calendi et al., 1965), and this color change
can be prevented upon addition of DNA.
These spectral changes of daunomycin upon addition of DNA indicate that the drug binds to both native and denatured DNA.

However, this

binding is greatly reduced with derivatives of daunomycin where there is
an alteration on amino sugar or complete removal of daunosamine, indicating that the amino group of daunosamine is actively involved in the
binding process.

I.2.7.2.

Evidence for Intercalation

Upon binding to daunomycin, there are also many changes in the
physico-chemical properties of double-stranded DNA.

These changes in-

elude a) an increase in the intrinsic viscosity of DNA (Zunino, 1971), b)
a decrease in the buoyant density of DNA (Kersten et al., 1966), c) a decrease of the sedimentation coefficient of DNA (Calendi et al., 1965;
Kersten et al., 1966), d) a stabilization of DNA against thermal denaturation, or in increase in the melting temperature of DNA (Zunino et al.,
1972) and e) a protection of DNA from degredation by nucleolytic enzymes
(nucleases)

(Zeleznick et al., 1967).

According to Lerman's hypothesis on the interaction of 9-aminoacridine with DNA, and increase in the intrinsic viscosity of DNA when
bound to antibiotics is accepted as a diagnostic feature of an intercalation

process

(DiMarco et al., 197lb).

--

This phenomenon is attributed to

a stiffening and elongation of the double-stranded DNA molecules when
drugs are inserted into the hydrophobic areas between the flat base pairs
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of the DNA helix (Evans et al., 1973).

Besides, the planar aromatic ring

system of daunomycin meets the requirement for the intercalation theory
in which the drug must be "flat" to fit the space between by the base
pairs (Gabby et al., 1976).

The intrinsic viscosity of DNA is markedly

less enhanced by all the derivatives of daunomycin with altered amino
sugar than by other derivatives containing unsubstituted daunosamine
(Calendi et al., 1965) indicating again that the amino group on daunosamine contributes to strengthening the intercalative binding.
In contrast to its effects on the native DNA, daunomycin causes
a marked decrease in intrinsic viscosity of denatured DNA.

This effect

parallels the results reported for acridine dyes (Drummond et al., 1966).
In the case of acridine dyes the effect of binding on the intrinsic viscosity of denatured DNA is quantitatively the same as that achieved by
adding neutral electrolyte and has usually been attributed to a decrease
in mutual repulsion between the charged groups of a flexible polyelectrolyte chain (e.g. phosphate groups) of DNA.

The effect of daunomycin

binding on denatured DNA could be explained by the effects of the positively charged amino groups of daunosamine on the mutual repulsion of the
phosphate groups, suggesting that daunomycin also, like acridines, binds
in the non-helical regions of DNA as in the denatured state (Zunino et
al., 1972).
The decrease of the sedimentation coefficient of daunomycin.-bound
double-stranded DNA is explained by the uncoiling of the helix at the
point of drug insertion which alters the average pitch on the helix and
causes an increase in the average number of base pairs per turn (Di Marco
et al., l97lb).
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The increase in the melting point (Tm) of DNA upon binding to
daunomycin indicates that there is an interaction between daunomycin and
DNA which stabilizes the association of the two strands (Calendi et al.,
1965).

This increase in Tm is dependent upon the drug to DNA ratio

(Zunino et al., 1972).

Very little increase in Tm is observed for N-

acetyl daunomycin and other derivatives with substitution in the amino
sugar moiety, again indicating that the amino group is actively involved
in stablizing the intercalated complex.
Daunomycin can be removed from DNA by Mg

2+

and it can be extrac-

ted from aqueous solution of the complex by organic solvents such as
phenol or n-butanol (DiMarco et al., 1972); at high ionic strengths, the
binding of daunomycin to DNA is reduced (Bhuyan et al., 1965).

Therefore,

it seems that the complex formation involves electrostatic forces.
Formamide, a hydrogen bond breaker, was found to revert completely

the binding between N-acetyl derivatives and DNA and only par-

tially that between daunomycin and DNA (Calendi et al., 1965).

This

suggests that some of the bondings between the drug and DNA is of hydrogen bond type and the amino groups of the sugar moiety imparts to daunomycin a much higher binding ability by providing greater possibility for
hydrogen bonding.
Other results correlate the structure of daunomycin and its derivatives with their biological activities.

It has been shown that when-

ever the amino hydrogen of daunosamine is not substituted and the CO
group of the acetyl side chain on position C-9 is not altered, the compounds are found to complex strongly to DNA and to inhibit mitotic activity,

DNA synthesis and cell proliferation (Zunino et al., 1972).

When
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the CO group of the acetyl side chain is altered, the derivatives preserve the ability to bind to DNA but with reduced antimitiotic activity
and are inactive or slightly active in inhibiting DNA synthesis and
cellular proliferation.

It has been shown (Arcamone et al., l964b) that

daunosamine, the amino sugar moiety of daunomycin, is an L-sugar, characterized by L-lyxo conformation.
~-D-glucosamine

When daunosamine is substituted with

or whenever the amino group is masked, the derivatives

are found to bind to DNA very weakly and to lack biological activity
(DiMarco et al., l97lb).

This suggests the importance of the structure

and of the stereochemistry of the amino sugar moiety in the binding
reaction.
All of these results have suggested two modes of binding between
the antibiotic molecules and DNA:

(l) the "strongly" bound antibiotic

molecules are understood to be intercalated between successive base pairs
of the double helix by the planar chromophore of the drug, facilitated by
the positively charged amino sugar;

(2) the "weakly" bound antibiotic

molecules are thought to be attached to DNA by means of electrostatic
interaction, involving the single-stranded DNA phosphate groups and,
again, the daunosamine amino group.

The shape of the isotherm (e.g.

Figure 8) for the binding of daunomycin to DNA from spectrophotometric
analysis (Zunino et al., 1972), the chromatographic behaviour of daunomycin on DNA-cellulose column (Zunino, 1971) and.the X-ray-diffraction
studies (Pigram et al., 1972) all support the intercalative model and
the secondary binding of daunomycin to DNA.
This intercalation theory can be used to explain the machanism
of the inhibitory activity of daunomycin or bacterial and animal viruses
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mentioned earlier.

In fact, from the previously discusseddata, it seems

that inhibition of the function or of the replication of the viral genome
requires the formation of a strong association of the antibiotics with
the nucleic acids, and, from physico-chemical studies, it is known that
this strong binding of drug to DNA occurs only with double-helical DNA
(Zunino et al., 1972).

The lack of activity on single-stranded DNA

(Calendi et al., 1966) or RNA (Cohen et al., 1969) viruses appears to be
a direct consequence of the inability of the drug to form this stable
binding.

I.2.7.3.

Models for Intercalation

An initial intercalation model was proposed in which the amino
sugar of daunomycin is in the major groove of the DNA (Pigram et al.,
1972).

In this model the conformation of ring D of daunomycin was taken

to be that found for the crystal structure of N-bromoacetyl daunomycin
(Angiuli et al., 1971).

In this structure C-9 is the most out of plane

atom and the sugar is oriented axially with respect to ring D (Figure 4,
conformation A).

In this DNA-binding model, the daunomycin amino group

binds to the second phosphate residue away from the intercalation site,
and there is a hydrogen bond between the C-9 hydroxyl group and the first
phosphate from the intercalation site (Goodman et al., 1977).

A more

recent analysis (Plumbridge et al., 1977) of the crystal structure of
daunomycin however, suggests a slightly different preferred conformation
of ring D (Figure 4, conformation B) in which C-8, rather than C-9, is
the most out of plane atom and in which there is a hydrogen bond between
the C-7 oxygen and C-9 hydroxyl group.

The DNA-binding model, therefore,
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Figure 4.

The structure of daunomycin showing (a) the conformation

of ring D for the crystal structure of N-bromoacetyldaunomycin,
(b) that found for daunomycin, and (c) an alternative conformation
for ring D.
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needs to be revised to incorporated this intramolecular hydrogen bond.
The conformation of ring D when the drug is bound to DNA may differ from
the preferred conformation found in the crystal form.

If the ring D

conformation is altered so that C-8 lines behind rather than in front of
the plane of the ring system as shown in Figure 4 then the amino sugar
becomes oriented equatorially rather than axially (Figure 4, conformation

c).

Consequently there will be a spatially different interaction of the

amino sugar in the major groove of the DNA (Pigram et al., 1972).

The

amino group will now bind to the first phosphate away from the intercalation site and there can be additional bonding in the form of hydrogen
bonds between the C-4' hydroxyl group and the second phosphate from the
site and between the C-9 hydroxyl and the phosphate at the intercalation
site (there is no intramolecular hydrogen bond between the C-7 oxygen
and the C-9 hydroxyl when the amino sugar is equatorial with respect to
ring D).

This latter model, therefore, provides for increased secondary

stabilization of the intercalation complex.

An inherent preference for

daunomycin binding to A-T base pairs is also present (Plumbridge et al.,
1979).

In all of these models, the C-14 hydroxyl group of adriamycin can

additionally hydrogen bond with the DNA.

This additional bond provides

the basis for the higher potency of adriamycin as compared to daunomycin
in their antitumor effects (DiMarco et al., 1969).
Analogs of daunomycin have been used to test the validity of the
main features and the fine details of these models (Brown, 1978; Arcamone,
1977).

However, these studies have not shown conclusively whether the

analogs bind by the reinforced intercalation mechanism as shown in Figure
4 conformation C.
All of the models for daunomycin and DNA interactions suggests
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that the binding will be more sensitive to changes in the sugar unit than
in the C-9 substitutents.

Consequently the effect of inversion of con-

figuration at C-7, C-1', C-3' and C-4' and the effect of deletion of C-4'
hydroxyl group, on the mechanism of binding to DNA were studied (Arcamone
et al.,
-

1976; Zunino et al., 1977; DiMarco et at., 1977; Plumbridge et

--

al., 1978).

It was found that the reinforced intercalative binding to

DNA which is typical of daunomycin can also occur if epimerization is
present at C-4' or if the a-methyl group is lost or if the C-9 substitute
is deleted or if the 4'-hydroxyl group is absent.

In the latter two

cases, however, there is a reduction in affinity for DNA, supporting the
suggested role of the 9-hydroxyl and 4'-hydroxyl groups in the secondary
stabilization of the complex.
Epimerization at C-1' or at C-3' alters but does not abolish the
intercalative mode of binding to DNA whereas epimerization at C-7 preeludes intercalation of the chromophore into the helix of DNA (Plumbridge
et al., 1979).

All of these results tend to support the binding model in

which ring D adopts conformation C in preference to the other binding
models.
In a separate report (Rich et al., 1981) a crystal of two daunomycin molecules intercalating into a double helical DNA was obtained. The
DNA contains two strands of a self-complementary hexanucleoside pentaphosphate, d(CpGpTpApCdG).

The saturation level for this intercalated

complex is one daunomycin per three base pairs.
X-ray diffraction studies revealed that the chromophore (rings
A through D, Figure 5) intercalates into DNA with ring A protruding well
into the major groove formed between base pairs Cl-G6* and G2-C5*.

Ring
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Figure 5.

Intermolecular attractions of intercalated daunomycin

and d(CpGpTpApCpG)
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D of the chrornophore and the attached amino sugar were found in the minor
groove between base pairs G2-C5* and T3-A4*.

Conformational changes for

DNA molecules were also detected in this intercalated complex.

Specifi-

0

cally, base pairs are displaced by 1.3 A toward the major groove.

An 8°

unwinding of the DNA also takes place at the base pair one removed from
the intercalation site.
Tight hydrogen bonding are also formed in this intercalated cornplex.

Figure 5 shows that the hydroxyl group on 09 forms a hydrogen bond

with N3 of G2 by donating its hydrogen.

This hydroxyl oxygen also re-

ceives a hydrogen from another amino group of G2.

In the case of adria-

rnycin, the 14 hydroxyl group could form additional hydrogen bonding with
03' of G2.

These hydrogen bonds may provide "anchoring function" holding

the antibiotic to the double helix.
According to this data, ring D seems to adopt conformation A in
Figure 4 which places the positively charged amino group in the minor
groove where it is well separated from the negatively charged phosphate
groups on either side.

I.2.8.

I.2.8.1.

The Mechanism of RNA and DNA Synthesis Inhibition by Daunomycin
and Its Analogs

Inhibition of RNA Synthesis

The formation of a complex between template DNA and RNA polyrnerase is essential for the synthesis of RNA (Hinkle et al., 1972a-d).
It was found that daunomycin has no effect on the activities of the RNA
polymerase enzyme per se, since the pre-incubation of the enzyme with
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the inhibitor in the absence of the template does not affect the activity
of the polymerase (Zunino et al., 1974).

Base on these information it

seems that the reduction of RNA polymerase activity could then be accounted for by the loss of template activity of the drug-treated DNA.

The

finding that daunomycin causes a marked drop in the formation of a complex between RNA polymerase and DNA template (Mizuno et al., 1975) indicates that the binding of daunomycin to DNA may give rise to steric hindrance effects that interfere with the association of the template to RNA
polymerase and thus, result in RNA synthesis inhibition.

Experimental

support comes from the finding that there is a competitive inhibition of
daunomycin and DNA template in RNA synthesis in which inhibition can be
overcome by readdition of the template (Zunino et al., 1974).

On the

contrary, a non-competitive relationship was established between the drug
and the RNA polymerase enzyme, indicating that the inhibition is predominently due to the interaction of daunomycin with template DNA.
was also noted that Mg

2+

It

could reverse the inhibitory effect of dauno-

mycin in RNA synthesis presumably by releasing the drug from the drug-DNA
complex (Calendi et al., 1965) thereby freeing the DNA template so that
it can be associated with RNA polymerase for transcription.

All of these

results suggest that the inhibition is due to the formation of a reversible inhibitor-DNA complex which reduces the capacity of DNA to bind RNA
polymerase.
The mechanism of RNA polymerase inhibition by daunomycin has
also been studied in terms of the preferential binding of the drug to
specific base pairs of the template, but the results from such reports
have conflicted.

Studies with DNA obtained from different sources
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revealed that the binding of daunomycin to DNA increases as the G-C
content of DNA increases (Zunino, 1971).

Kersten also reported that

the conformational changes of the daunomycin chromophore upon complex
formation with DNA are slightly dependent on the G-C content of DNA
(Kersten et al., 1971).

However, inhibition studies of the DNA-

dependent RNA polymerase by daunomycin (Ward et al., 1965) showed that
daunomycin inhibits DNA-dependent RNA polymerase activity irregardless
of the G-C content of the template used.

Recent reports, from the study

of the interaction between daunomycin and short segments of double helical DNA (Rich et al., 1981), also indicate that although highly specific
hydrogen bonds, which serve to hold the antibiotic to the double helix,
can be formed between daunomycin and G-C base pairs, such bond do not
suggest great selectivity, i.e., when adenine is present instead of
guanine, different but still highly stable hydrogen bonds can also be
formed with daunomycin.

Furthermore, results from model building

(Plumbridge et al., 1979) suggest that daunomycin has a preference for
A-T sequence and the stabilization of double helix by daunomycin appears
to be dependent on the A-T content in DNA (Zunino et al., 1974).

Other

inhibition studies also showed that DNA templates which contain poly(dA·
dT) are more sensitive to the action of daunomycin (Bhuyan et al., 1965).
These results are supported by the observations that the inhibitory action
of daunomycin is most effective at later stages of cell division (later
S, G and M) in mammalian system (Mizuno et al., 1975; Silvestrini et al.,
2
1970).

At this stage the drug preferentially binds to the heterochromatin

fraction which is rich in adenine-thymine (Yunis et al., 1971}.
tion, studies with synchronized rat fibroblasts

In addi-

(Silvestrini et al., 1970)

32

showed that the high sensitivity of RNA synthesis to daunomycin in G
2
phase is related to the fact that DNA containing poly (dA•dT) sequences
are being transcribed at this time (Becker, 1972).

It seems, therefore,

that the extent of inhibition may be not only a function of the base composition of DNA but also of the secondary structure of DNA (Bram, l97la)
as well as the complexity of nucleotide sequence (Bram, l97lb) of the
DNA segment that is being transcribed.
The regulation for gene expression (via transcription) in eukaryotic cells appears to involve multiple forms of RNA polymerase (Widnell
et al., 1966).

It was discovered that RNA polymerase A (or I), which is

located in the nucleolus, is responsible for the synthesis of rRNA.
polymerase

B

RNA

(or II), which is located in the nucleoplasm is responsible

for the general synthesis of mRNA. These enzymes can be distinguished by
their sensitivity to

~-amanitin;

RNA polymerase A is insensitive, RNA

polymerase B is completely inhibited (Chambon, 1975).
merase A is activated by Mg

2+

Also, RNA poly-

whereas RNA polymerase B is activited by

It was discovered that daunomycin preferentially inhibits the
incorporation of tritiated uridine into ribosomal RNA components (Dana
et al., 1972).

The synthesis of heterodisperse, high molecular-weight,

nucleoplasmic RNA has little sensitivity to inhibition by daunomycin,
whereas the synthesis of tRNA, SS

~~A,

and two small molecular-weight

RNA components (Components C and D) shows medium sensitivity to daunomycin.

In contrast, daunomycin inhibits the synthesis of l8S and 28S

rRNA and the nuclear 45S and 32S precursors strongly and to the same
extent, indicating that it is the synthesis of 45S RNA that is inhibited
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and not the processing of 45S RNA to rRNA.

This preferential inhibition

of rRNA by daunomycin is supported by electron microscopic studies
(Rusconi et al., 1964) and autoradiographic studies (DiMarco et al.,
1965) in Hela cells.

One explanation for this preferential inhibition

is found in the findings that heat denatured DNA is more transcribed than
the native DNA by RNA polymerase B (Barthelemy et al., 1976) and it takes
much higher concentration of daunomycin to inhibit RNA polymerase activity using denatured DNA as template (Zunino et al., 1975).

This is an-

other piece of indirect evidence to support the intercalative theory of
inhibition in which the double-stranded DNA is required for strong binding and inhibition.

Native DNA, on the other hand, is a better template

for RNA polymerase A and thus is inhibited by the intercalating daunomycin to a much greater extent.
Some preliminary proposals for the mechanism of RNA synthesis
inhibition by daunomycin have been reported.

Daunomycin has been found

to reduce the formation of a complex between RNA polymerase and DNA because the drug-DNA complex provides the template a different conformation which is unable to bind RNA polymerase (Mizuno et al., 1975; Section
I.2.8.1.).

A later study with DNA extracted from Ehrlich Ascites tumor

cells (Barthelemy et al., 1976) revealed that the presence of daunomycin
also greatly increases the rate of dissociation of the enzyme-template
complex.

It was speculated in this study that daunomycin probably inter-

feres with the melting of the double stranded DNA by RNA polymerase at
the binding site (which transforms the enzyme-DNA complex into a stable
one for RNA synthesis initiation,

(Meilhac et al., 1972; also see Section

I.3.4., and Figure 6)) and therefore de-stabilizes the enzyme-DNA complex
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for RNA synthesis.
Since elongation of RNA strands does not seem to be affected
significantly by daunomycin (Schellinx et al., 1979), it appears that
once the first phosphodiester bond is formed, dissociation of daunomycin
from the opened helix is fast enough not to be rate limiting.

I.2.8.2.

Inhibition of DNA Synthesis

Very little effort has been made in the study of the mechanism
of DNA polymerase inhibition by daunomycin or adriamycin.
available information is at

The currently

best conflicting and inconclusive.

For ex-

ample, in a system using salmon spearm DNA and T4 DNA polymerase (Goodman
et al., 1974; Goodman and Lee, 1977) it was determined that DNA synthesis
is inhibited by adriamycin via inactivation of the template functions.
Both intercalative and ionic types of binding of the drug to DNA were
found to occur and the relative amounts of each type of binding may depend upon the relative drug to DNA ratio.

At low drug to DNA ratio, the

intercalation is favored, while at high drug to DNA ratio, the ionic
interactions become additional forces for DNA synthesis inhibition.
A separate study (Tanaka et al., 1980) showed that inhibition of
DNA synthesis by daunomycin and adriamycin is mainly the result of direct
interaction of drug molecules with DNA polymerase rather than the result
of drug impairing of the template activity of DNA due to intercalation.
Apparently stronger inhibition is produced by pre-incubating the drugs
with enzyme rather than with the template-primer complex.
The reason for the discrepancies between these results is not
clear.

It is apparent, however, that the mechanism of inhibition of
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both RNA and DNA synthesis by daunomycin and its analogs are still poorly
understood.

Additional studies are necessary to determine the mechanism

of the inhibition process and to resolve conflicting reports.

I.2.8.3.

Factors Affecting the Inhibition Studies

Conflicted

results have also been reported on the comparative

study of the extent of inhibition by daunomycin in the incorporation of
labeled precursors into RNA and DNA in vivo or in cultured cells.

-- ----

In vitro studies on Ehrlich ascites tumor cells (Dano et al.,
1972) and on Ll210 mouse leukemia cells (Meriwether et al., 1972) showed
that daunomycin inhibits DNA and RNA synthesis to a similiar degree.
Other in vivo studies support this result (Rusconi et al., 1969; Meriwether et al., 1972).

However, some studies showed that DNA polymerase

is more sensitive to daunomycin inhibition than RNA polymerase (Mizuno
et al., 1975; Momparler et al., 1976).

These discrepancies may be due

to the different experimental conditions employed, since studies with
Hela cells demonstrated that at low daunomycin concentrations RNA synthesis is more inhibited than DNA synthesis whereas at high drug concentrations both DNA and RNA synthesis are inhibited to the same degree
(Rusconi et al., 1969).
Cell population densities also affect the response of the cells
to inhibition.

In fact, the inhibition of RNA or DNA synthesis is lower

when then cell number is relatively high even though the relative uptake
or the amount of daunomycin bound to DNA remains the same as when the
cell number is relatively low.

Autoradiographic studies have provided

evidence that, in synchronized cells, the uptake of the antibiotic also
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varies according to the phase of the cell cycle (Silvestrini et al.,
1963).
Discrepancies have also been reported on the relative inhibitory
potency of daunomycin and adriamycin.

Evidence from cell culture (Meri-

wether et at., 1972) and cell free systems (Zunino et al., 1975) show
that even though daunomycin and adriamycin inhibit both DNA and RNA
synthesis to the same extent, daunomycin appears to be a better inhibitor
in cell culture than adriamycin whereas adriamycin appears to be a better
inhibitor in the cell free systems.

However, it was shown that the up-

take of daunomycin by the cells is much greater than that of adriamycin,
indicating that the actual effectiveness of adriamycin could be higher
than that of daunomycin.

Some in vivo

studies with animals (Sandberg

et al., 1970) and preliminary clinical studies (Bonadonna et al., 1970)
showed a higher therapeutic index for adriamycin.
All of these studies have lead to the conclusion that the understanding of the mechanism of daunomycin action is still far from clear
and that more than one mechanism of inhibition could be operating in the
intact animals.

For example, mechanisms involving differences in the

rates of drug uptake and routes of drug excretion, differences in protein binding, differences in metabolic pathways, or different rates of
metabolism in vivo

for each drug probably play important roles in deter-

mining the overall drug effectiveness in vivo.
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I.3.

Mechanism of Transcription
DNA-dependent RNA polymerase is responsible for the synthesis of

all cellular RNA and thus plays a central role in the process by which
the genetic information encoded in DNA is expressed.

The information

presented in this section pertains to bacterial RNA polymerase, unless
specified otherwise.
The prokaryotic transcriptional process catalyzed by bacterial
RNA polymerase can be formally separated into several steps, including
binding of the enzyme to the template, initiation steps which yield a
tight complex of RNA polymerase with the promoter and opening the doublestranded structure at specific sites allowing the formation of the first
phosphodiester bond.

This is followed by elongation using one strand as

a template to direct the synthesis of a complementary RNA molecule, and
finally termination, in which the product RNA is liberated and the enzyme
becomes available for the next cycle (Zillig et al., 1976).

I.3.l.

Structure and Composition of Bacterial RNA Polymerase
Bacterial DNA-dependent RNA polymerase is a multisubunit enzyme.

Holoenzyme monomers from various sources contain two large subunits,
and

(molecular weight 160,000), two identical small

~

~·

subunits,~(molecular

weight 40,000), and an initiation factor, 6(molecular weight ranging from
44,000 to 92,000 (Lill et al., l975a; Palm et al., 1975)).

Holoenzyme

(~·~~ 6)

can be separated into two functional parts:

(~·~~

which is able to initiate RNA synthesis but lacks the ability to

2

2)

a core enzyme

initiate such synthesis at specific sites on the template (Chamberlin,
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1976}; and the sigma factor (6), which enables the enzyme to select a
specific initiation site on the template (Burgess, 1971) by recognizing
a particular base sequence termed "promoter".

The sigma factor is re-

leasedduring chain elongation (Travers and Burgess, 1969).
sitution of

The recon-

holoenzyme from these two components occurs rapidly when

the two are mixed in solution (Berget al., 1971) and the reconstituted
holoenzyme regains the ability to initiate specific RNA chains.

I. 3. 2.

Functions of the Subunits of RNA Polymerase

Dissociation of the enzyme with SDS or high concentration (SM)
of urea leads to complete separation of all the subunits of the enzyme;
these subunits can then be resolved from each other by electrophoresis or
acrylamide gel or by sizing chromatography (Travers and Burgess, 1969;
Heiland Zillig, 1970).
~·,the

most basic subunit of RNA polymerase (Rexer et al., 1975)

is able to bind to DNA whereas the other subunits which are less basic, or
the subassembly
bind to DNA.

~~

2

(Fukuda et al., 1974: Yarbrough et al., 1974) do not

Therefore

(Sethi et al., 1971).
binds to

the~·

~·

has been designated as the DNA-binding subunit

Heparin, a polyanionic transcription inhibitor,

subunit (Zillig et al., 1971) and competes with DNA for a

template binding site on the polymerase (Walter et al., 1967) and therefore provides further evidence for the DNA binding function of
It has also been shown (Stetter et al., 1974)
site

for~-

During transcription

~is

that~·

~·

subunit.

contains a binding

released from the active complex

of RNA polymerase, template and product when the product has reached a
critical length of about ten nucleotide residues (Krakow et al., 1971).

39

It has been suggested
(which might

that~

involve~')

is bound to the "product site" of the enzyme

and is displaced by the growing RNA strand

(Zillig et al., 1976).
The understanding of the functional role of

~

subunit comes from

the studies involving rifampicin which binds to RNA polymerase (Wehrli
et al., 1968) and inhibits the initiation of RNA synthesis (Sippel et al.,
1968).

RNA polymerases from mutants resistant to the drug do not bind

the drug and show a

~

subunit with an altered electrophoretic mobility

(Rabussay et al., 1969).

~subunit

also has been found to be directly

involved with streptolydigin, another antibiotic which interacts with
core RNA polymerase and inhibits elongation of RNA chains (Siddhikol et
al., 1969).

Therefore

the~

subunit contains the antibiotic binding

sites and is responsible for the catalytic functions (both initiation and
elongation) of the enzyme.
Subunit cJ.. is present in solution as a dimer (Lill et al., l975b)
in which the twodchains are linked by a disulfite bridge (Zillig et al.,
1976).

The function of o<. is not clear at the moment, although it has been

suggested that in addition to

~, ~

and

~·

are required for reconstitution

of the catalytically active holoenzyme (Chamberlin, l974a)
quired to

bind~

in order to

activate~

and~

is re-

for drug binding (Lill et al.,

l975a).
These assignments of specific functions to the various subunits
are still somewhat tentative, particularly due to the lack of knowledge
about the primary and three dimensional structure of the enzyme.
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I.3.3.

Binding of RNA Polymerase to DNA

In the presence of an excess of RNA polymerase, whether it be
halo- or core-enzyme, helical DNAs such T7 can bind an amount of RNA
polymerase limited only by the steric interactions between enzyme molecules (Pettijohn et al., 1967).

Hence RNA polymerase possesses a sub-

stantial general affinity for DNA that is not sequence-specific (Hinkle
et al., 1972a).

This general affinity is called the non-specific bind-

ing and is entirely electrostatic in nature (Record et

al., 1976). The

binding constants for either core- or holo-enzyme are not highly temperature sensitive, indicating that the bindings do not involve opening (or
melting) of DNA base pairs (Saucier and Wang, 1972).

The association

constant for general binding of RNA polymerase holoenzyme and core8
9 -1
11 -1
enzyme to T7 DNA were estimated at 10 -10 M and 10
M respectively
under normal reaction condition in 0.01 M Mg
and Chamberlin, 1972a).

2+

and 0.05 M Na

+

(Hinkle

The substantially higher binding constant for

core enzyme than that for holoenzyme suggests that binding of sigma subunit supresses the general binding affinity of core polymerase for DNA
(Chamberlin, 1974b) except at promoter sequences (see next section).
Core polymerase is able to catalyze the synthesis of RNA chains
but is unable to locate promoter sites to form the highly stable RNA
polymerase-promoter complexes with DNA template.

Therefore core-poly-

merase-DNA complexes are highly sensitive to attack by heparin (Hinkle et al., 1972c) and rifampicin (Bautz and Bautz, 1971), which indicates a slow rate of RNA chain initiation by these complexes.

It was

also found that single-stranded breaks are the primary sites for initiation by core enzyme (Hinkle et al., 1972c) probably because of the fact
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that DNA-core enzyme complexes are defective in opening the DNA strands,
which is necessary in transcription (Saucier and Wang, 1972).

Site Selection of RNA Polymerase Holoenzyme

!.3.4.

In systems where RNA polymerase carries out selective transcription, effective binary complexes are formed primarily at promoter regions
of the DNA template.

The specificity of the process of "site selection"

involves the binding interaction which positions RNA polymerase on the
template and the subsequent interactions between the enzyme and DNA at
that site that render the complex effective in the chain initiation reaction.

This process of promoter "site slection" is a key point at which

cellular regulation of transcription takes place.
Under appropriate reaction conditions, RNA polymerase holoenzyme
and DNA template form stable binary complexes which can go on synthesizing
RNA with

spe~ific

5'-termini (Pribnow, 1975).

The formation of these

stable complexes is dependent upon the rapid dissociation of the nonspecific complexes mentioned in the last section.

Studies from T7 DNA

and E. coli RNA polymerase holoenzyme showed that a maximum of eight
enzyme molecules are tightly bound to T7 DNA with a binding constant of
10

12

-10

14

-1
M

.

(H~nkle

et al., 1972a).

A limited number of base pairs

(six to seven) are opened in the complex (Saucier and Wang, 1972) with
the RNA polymerase acting as a sequence-specific melting protein (Mangel
and Chamberlin, 1974a).

This opening process is temperature dependent

and the complexes formed have been termed "open promoter complexes"
(Mangel and Chamberlin, 1974b).
With T7 DNA, open promoter complexes are not formed at low ternperature; as the temperature is increased, however, there is a coopera-
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tive transition with a midpoint of about 18 °C (transition temperature),
and above this temperature complex formation is eventually complete (Mangel and Chamberlin, l974a).

The enthalpy for this melting reaction is

calculated at 57 Kcal per mole (Mangel and Chamberlin, l974a).

This

opening is essential to the subsequent binding of the nucleoside triphosphates in the chain initiation step (Chamberlin, 1976).
In conclusion, the sequence of steps in site selection by RNA
polymerase holoenzyme involves (l) reversible, weak binding to random
sites on DNA to form non-specific complexes, leading to (2) attachment
to a site at or near the specific site (promoter) on the T7 DNA molecule
to form the closed promoter complex (I complex) and (3) a reaction to
form a highly stable complex, the open promoter complex (or RS complex)
with the separation of the DNA strands at or near the promoter sites
(Zillig et al., 1971).

The open promoter complex is able to initiate the

formation of the first phosphodiester bond to form the OP complex.

A

scheme depicting all these pre-initiation events is presented in Figure 6.

I.3.5.

Assays for the Rate of RNA Initiation

Several assays for the rate of RNA chain initiation have been
developed (Mangel and Chamberlin, l974a,b,c) by exploiting the property
of the drug rifampicin to attack and inactivate RNA polymerase molecules.
It was discovered that both free E. coli RNA polymerase and RNA polymerase bound to T7 DNA template are attacked by rifampicin in secondorder reactions although the rate constant for the latter is 100-fold
slower (Hinkle et al., l972d).

In contrast, the elongating enzyme mole-

cules are insensitive to the attack of rifampicin (Sippel and Hartman,
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Figure 6.
Synthesis

Promoter Recognition and Initiation of RNA
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1.

Intermolecular Exchange
(non-specific complexes)
2.

Initial Recognition
(I complex)

ppp

ATP, GTP, UTP,CTP

4.

Initiation
(OP complex)

3.

Activation
(RS complex)
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1968).
Another important feature in these assays is the time under
which the RNA synthesis is allowed to proceed.

The in vitro transcrip-

tion of T7 DNA by E. coli RNA polymerase is restricted to the early
region consisting of about 20% of the r-strand of the T7 duplex (Davis
and Hyman, 1970), which yields an RNA product of approximately 7,000
nucleotides long (Millette et al., 1970).

Since the rate of the chain

growth is rapid (about 40 nucleotides per second for T7 DNA (Davis and
Hyman, 1970)), termination and re-initiation could take place within a
few minutes.

Therefore the reaction time in these assays is limited to

90 seconds to eliminate the possibility of termination and re-initiation.
Utilizing this information two assays were developed to measure
the rate of I complex to RS complex transformation and the rate of RS
complex to OP complex transformation.

The detailed descriptions of these

assays are presented in section III.3.4.2.

I.3.6.

Other Properties for Promoter Sites

The formation of open promoter complexes is affected by the
structure of the RNA polymerase involved, the structure and nucleotide
sequence of the DNA template, other components present in solution and,
finally, the reaction temperature.
The open promoter complex has a high stability to dissociation
with half-lives of many hours under standard ionic conditions (0.01 M
Mg

2+

+
, 0.05 M Na ) .

At low temperature or high ionic strength, the

stability of the complex is greatly reduced (Seeburg and Schaller, 1975).
The RNA polymerase in open promoter complex is monomeric (Beabealashvilly
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et al.,l972) and is attacked at a reduced rate by rifampicin (Hinkle and
chamberlin, 1972d) and polyanion heparin (Zillig et al., 1971).

It is

able to initiate an RNA chain rapidly when presented with nucleoside triphosphate substrates (Mangel and Chamberlin, 1974c).
Promoter sites display a definite specificity for a particular
RNA polymerase.

The T7-specific enzyme, for example, does not utilize

any of the promoter sites on T3 DNA that are read by the T3-specific
enzyme (Golomb and Chamberlin, 1974), nor does it read E. coli RNA polymerase promoter sites on T7 DNA.

Therefore, each promoter has the se-

quence information essential for its utilization by a particular RNA
polymerase (Chamberlin, 1976).
Promoter sites on the same DNA differ in their rates of utilization (Heyden et al., 1972).

With T7 DNA, for example, a major fraction

of the RNA formed with E. coli RNA polymerase at low ratios of enzyme to
DNA is initiated at three closely linked promoter sites (Al, A2, A3) at
the early region of the molecule (Dunn and Studier, 1973; Daussee et al.,
1972).

These three sites are used with approximately equal effeciency at

37°C, but at low temperature (10-l5°C) or high ionic strength of the reaction mixture, site A3 is used over 50% of the time (Daussee et al.,
1972).

In addition to these so called "major" promoter sites, "minor"

promoter sites, which are used with lower effeciency except when excess
enzyme is present, are also located in the early region of the T7 genome
(Minkley and Pribnow, 1973), but it is not known whether these sites are
functional in vivo.
Major promoter sites can also differ from the minor sites in the
strength of the melting interaction between the promoter and the RNA
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polymerase.

Under conditions which reduce the melting reaction (i.e.,

low temperature) a major promoter will be read at a reduced rate and
becomes a minor promoter (Richardson, 1975).

At higher temperatures

or in the presence of DNA de-stabilizing agents these promoters are activated and begin to be read at a substantial rate (Richardson, 1975;
surzycki, 1976).

However, for some minor promoters, conditions that

facilitate the melting interaction do not alter the relative rate of
reading (Golomb, 1974b).
For certain promoter sites, such as that governing the lac
operon, transcription by E. coli RNA polymerase alone is very slow unless
a cyclic AMP receptor protein is added along with cyclic AMP (Chen et
al., 1971; Anderson et al., 1974).

The cyclic AMP receptor protein was

found to reduce the melting temperature of DNA (Makanishi et al., 1974).
This positive control protein is also known to be essential for transscription in vivo (Chamberlin, 1976).
Repressor proteins suppress transcription at specific promoter
sites and block the formation of open promoter complexes by making the
promoter inaccessable to RNA polymerase (Squires et al., 1976) or acting
as anti-melting agents (Wang et al., 1974; Von Hippel et al., 1975).
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I.4.

Purpose and Scope for This Research Project

Recently the correlation between biological properties and
pharmacological effectiveness of a series of anthracyclines has been
examined.

Many attempts have been made to establish a relationship

between the effects of anthracycline bind to DNA and the resulting
stabilization of the double helix versus the antitumor activities of
the drugs.
Studies involving large number of structural analogs of
daunomycin have shown that the strength of DNA binding correlates in
general with antitumor activity (Nakanishi et al., 1974).

Since the

proposed mode of binding of anthracycline to DNA is intercalation, certain predictions regarding the DNA affinities of various daunomycin derivatives have been made on the basis of the structure of the resulting
anthracycline-DNA complex.

For example, the C-4' hydroxyl of the anth-

racycline sugar moiety was found not to take part in any interactions
and this suggests that epimerization at C-4' would produce derivatives
with no alteration in their DNA binding ability (Neidle, 1977).

This

indeed was found to be the case with 4'-epiadriamycin which intercalates
to DNA with the same affinity as its parent compound (Plumbridge and
Brown, 1978) and has equivalent activity against experimental tumors as
that of adriamycin (Arcamone et al., 1975).

It was also predicted that

since the C-4 methoxy carbon atom of daunomycin is not co-planar to the
heterocyclic ring, removal of this group should allow deeper insertion
of the ring into the intercalation site and therefore should increase
the affinity to DNA (Zunino et al., 1976).

Indeed 4-demethoxy derivatives
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of daunomycin have been found to enhance the thermal stability of DNA
to a larger degree than the parent compounds (Zunino et al., 1976).
Furthermore 4-demethoxydaunomycin is as effective against various experimental tumors as the parent compound but at doses four to eight times
lower than those effective for daunomycin (Arcamone et al., 1976).

Simi-

larly, 4-demethoxyadriamycin and 4-demethoxy-4'-epiadriamycin are effective against the same experimental tumors but at doses ten times lower
than those effective for adriamycin (DiMarco et al., 1978).

Therefore,

the present argument is that the structure of anthracyclines greatly
influence their binding properties to DNA and these binding properties
in turn correlate with the antitumor activities of these drugs (i.e.,
stronger binding increases antitumor effectiveness of the drug).
Although there is very little doubt that DNA binding affects
the antitumor activities of anthracyclines, there are now some indications that the strengths of association between anthracyclines and DNA
(i.e.,the association constant) may not be the most appropriate parameters to explain the correlation.

For instance, the higher potency of

4-demethoxydaunomycin compared to daunomycin is not consistent with the
similarity of the apparent association constants of these drugs with
DNA, which are 2.4 + 0.3 x 10
(Zunino et al., 1976).

6

-l
6 -1
M and 3.3 + 0.8 x 10 M respectively

Other findings have shown that upon binding to

DNA, anthracyclines stabilize the double helix (Zunino et al., 1972).
This suggests that the extent of double helix stabilization may provide
a better approach to correlate the biochemical and pharmacological activities of anthracyclines.

In fact 4-demethoxydaunomycin has been found

to be more effective in stabilizing the double helix than the parent
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compound (Zunino et al., 1976).

It should be noted that although this

property is partially dependent on the strength of association between
DNA and the drug, it is not strictly proportional to it.
Furthermore, studies on the effectiveness of the four stereoisomeric 4-demethoxydaunomycin derivatives (Figure 7) as potential antitumor agents have shown that inversions of configuration at position l
of the amino sugar and at positions C-7 and C-9 of the heterocyclic ring
markedly decrease demethoxydaunomycin binding to DNA, with the
binding less strongly.

~-anomers

In terms of double helix stabilization, the

~-

anomers are most effective with the 7,9-bis-epi derivatives producing
the least amount of stabilization (Zunino et al., 1976).

--

However, the

inhibitory effects of these series of isomers on the in vitro synthesis
of RNA correspond more closely to their stabilizing effects on the double
helix rather than their binding affinities to DNA.
Recently anthracyclines such as carminomycin, aclacinomycin,
marcellomycin, and musettamycin (Figure lc, d, e, and f) have been isolated or synthesized (Nettleton et al., 1977; Oki et al., 1975).

Car-

minomycin has a similar structure with daunomycin while the other three
anthracyclines are characterized by the presence of a carbomethoxy group
at C-10 position and a glycosidic side chain containingfrom two to three
sugar residues.

The amino group of the primary sugar residue for these

new anthracyclines is also substituted.

It has been shown that daunomy-

cin, adriamycin and carminomycin inhibit RNA synthesis at comparable
concentrations (DuVernay et al., 1980) whereas aclacinomycin, marcellomycin and musettamycin are more effective against RNA synthesis than the
previous group (Crooke et al., 1977; DuVernay et al., 1979).

However,
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Figure 7.

Stereoisomers of 4-demethoxydaunomycin

52

OH
COCH3
'OH
OH

•
0

OH

I1.
OH

I

4-demethoxydaunomycin
cJ..-anomer

f-0
4-demethoxydaunomycin
f3 -anomer

OH
OH

OH

I
I
I

•

OH

0

I1.
OH

I
I
I

I

f-0
7,9-bis-epi-4-demethoxydaunomycin o{-anomer
7,9-bis-epi-4-demethoxydaunomycin f3 -anomer

53

the mechanisms of RNA synthesis inhibition by these drugs remain unknown.
The mechanisms of RNA synthesis inhibition by ethidium bromide
and its analogs have been thoroughly studied (Aktipis and Panayotatos,
1977).

These drugs were found to inhibit primarily the initiation process

of RNA synthesis without affecting elongation to a significant extent.
subsequently the effects of these drugs on the rate of RNA polymerase-DNA
binary complex transformation processes prior to RNA synthesis initiation
were carefully examined.

It was concluded that even though no signifi-

cant differences were observed in the mechanism by which these drugs
inhibit RNA synthesis, the relative inhibitory effectiveness of ethidium
and its analogs depended not only on their relative binding affinities to
DNA but on the individual structural characteristics of these drugs as
well.

Thus, it is reasonable to expect that structural differences

between relatedanthracyclines may also influence the mechanism of inhibition of RNA synthesis to different extents, and that such differences may
not all be due simply to differences in the affinity with which each
anthracycline associates with the DNA template.
Previous attempts to correlate the biochemical properties of
anthracyclines, in terms of their DNA binding affinities and stabilization of double helical structures, with the pharmacological effectiveness
of these drugs have failed to provide consistent results.

In addition,

the mechanism by which anthracyclines inhibit RNA synthesis has generally
been overlooked in these studies.

It is the goal of this dissertation to

examine the mechanism by which anthracyclines inhibit RNA synthesis.

Once

the mechanism of RNA synthesis inhibition by each anthracycline analog
is determined, it would also be of interest to examine whether a correla-
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tion between the mechanism of inhibition and the template affinities of
these various anthracyclines can be established.

CHAPTER II

MATERIALS AND METHODS
II.l.

Materials
Bacteriophage T7 {host: E. coli B) was a generous gift from Dr.

D. Hinkle of the University of Rochester {Rochester, New York 14627).
The phage had a titer of 3.5 x 10

11

plaque forming units per ml.

E. coli B thymine requiring mutant strain was a generous gift
from Dr. Robert V. Miller of Loyola University of Chicago (Maywood,
Illinois 60153).
DNA-dependent RNA polymerase (Nucleosidetriphosphate: RNA nucleotidyltransferase; EC No. 2.7.7.6) from E. coli B., strain K-12 was
purchased from Sigma Chemical Company (St. Louis, Missouri 63178) as a
solution in 50% glycerol and 50% 0.01 M Tris buffer, pH 7.9, containing
0.1 M NaCl, 0.1 mMDithiothreitol and 0.1 mM EDTA.

The enzyme (Lots

108C-04491 and lOOF-00781) had specific activities of 1195 and 750 units/
mg, and consisted of 2.9mgproten/ml and 3.5 mg protein/ml, respectively.
One unit of enzyme will incorporate 1 nMole of labeled ATP into an acid
insoluble product in 10 minutes at pH 7.9 at 37°C, using Calf thymus DNA
as template {Burgess, 1969).
Daunomycin

{(8S-cis)-8-acetyl-10-(~-amino-2,3,6-trideoxy-~-L

lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxyl-l-methoxy5,12-naphthacenedione), a red crystalline solid, was purchased from
Boehringer Mannehim Biochemicals (Indianapolis, Indiana 46250) as hydrochloride, with a molecular weight of 564.0 daltons (Lot No. 1457501).
55
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4-demethoxydaunomycin (Lot No. GDA 2652/61) was a generous gift from
Dr. Federico Arcamone of Farmitalia Carloerba, Milano, Italy.

Crystal-

line solids of aclacinomycin (yellow, Lot No. 80Fl08), carminomycin
(orange, Lot No. 80F401), marcellomycin (dark red, Lot No. C36145-S369G55) and musettamycin (dark red, Lot No. C36145-S420-G25) were generous
gifts from Dr. J.L. MacBeth of Bristol Laboratories (Syracuse, New York
13201).

Marcellomycin and musettamycin were provided as free bases.

Rifampicin (m.w. 823 daltons) was purchased from Sigma.
White crystalline sodium salts of nucleoside triphosphates;
ATP, CTP, GTP, and UTP were purchased from P-L Biochemicals, Inc. (Milwaukee, Wisconsin 53205).

The commercial preparations were at least 97%

pure according to the manufacturer's specifications.
3
[5,6- H] uridine-5'-triphosphate, tetrasodium salt (specific
activity: 25 Ci/mmol) in ethanol:water (1:1) solution was purchased from
ICN Pharmaceuticals, Inc. (Irvine, California 92715).

The solvent was

removed by directing a gentle stream of nitrogen gas onto the surface
of the warmed solution (not exceeding 30°C) before use.

3

[Methyl- H]

thymine agueous solution (specific activity 30 Ci/mmol) was purchased
from Amersham Corporation (Arlington Heights, Illinois 60005).

All

radioactive materials were over 99% pure according to the manufacture's
specifications.
Nitrocellulose membrane filters (BA85, 24 mm, 0.45 micron) were
purchased from American Scientific Products (McGaw Park, Illinois 60085).
Whatman glass microfibre filters (GF/C, 2.4 em) were purchased from
Sargent-welch (Skokie, Illinois 60077).
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II.2.

Instruments:

The following instruments were used in this study:
Cary model 15 Recording Spectrophotometer (Varian, Cary Instruments Division, Monrovia, California 91016).
Beckman model LS-65 Ultracentrifuge (Beckman Instruments, Inc.
Fullerton, California 92634).
Beckman model LS 7500 Liquid Scintillation Counter with Microprocessor (Beckman Instruments, Inc. Fullerton, California 92634).
Sorvall RC-5B Refreigerated Superspeed Centrifuge (Du Pont
Instruments, Wilmington, Delaware 19898).
Barnstead Laboratory Sterilizer (Sybron Coporation, Downers
Grove, Illinois 60515).
Corning model 12-B Research pH Meter (Corning Scientific
Instruments, Medfield, Massachusetts 02052).
Mettler Pl63 Balance (Mettler Instrument Corporation, Highstown,
New Jersey 08520).
Perkin-Elmer model 320 Spectrophotometer (Perkin-Elmer Corporation, Norwalk, Connecticut 03016).
Pipetman Adjustable Pipet models P-1000, P-200, P-20 (Rainin
Instrument Co. Inc. Woburn, Massachusetts 01801).
Forma model 2563 Shaker Bath (Forma Scientific, Marietta, Ohio
40133).
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II.3.

II.3.l.

Preoaration of Working Solutions

Preparation of T7 DNA

Bacteriophage T7 was grown essentially as described by C.C.
Richardson (Richardson, 1966).
(Thomas and Abelson, 1966)

E. coli B was grown in a TCG medium

(0.8 ml, O.lOM Na

2

so 4 ;

450 ml H 0; 0.5 ml,
2

1.0 M MgS0 ; 1.0 ml, 25% NaCl; 0.1 ml, 0.5 M CaCl ; 1.5 ml, l mMFeCl ;
2
4
3
3.2 ml, 0.1 M KH P0 ; 50.0 ml, 1.0 M Tris-HCl, pH 7.4; 5.0 ml, 10%
2 4
glucose; 5.0 ml, 5% Casamino acids) in a culture flask with rapid swirling at 37°C.

T7 phages were added to the medium at a multiplicity of

0.1 when E. coli B had reached log phase.

Shaking was continued for 1

hour at 37° C to permit complete lysis of the cells.

The lysate was

centrifuged for 15 minutes at 10,000 g and the precipitate was discarded.
A rapid bacteriophage sedmientation method (Yamamoto and Alberts,
1970) was employed to purify and collect the phage particles.

The crude

lysate was cooled to 4° C and enough NaCl was added to bring its concentration up to 0.5 M.

Polyethylene glycol (PEG 6000) 6% (w/v) was

added into the crude lysate and the solution was let stand for at least
l hour at 4° C.

The phage pellet was collected after centrifugation at

10,000 g for 15 minutes and was resuspended in a minimum amount (l ml) of
sterile lMNaCl, 0.01 M Tris buffer (pH 8.0).

The phage suspension was

then purified by CsCl density gradient equilibrium centrifugation.
Sterile CsCl solutions of densities 1.1, 1.3, 1.5 and 1.7 g/ml (5 ml
each) were added in succession by introduction at the bottom of the tube.
The phage suspension was then layered on top of the CsCl solutions.
After centrifugation for 3 hours at 22,000 rpm and then 12 hours at

59
35,000 rpm the purified phage was collected and dialyzed overnight
against 0.1 M potassium phosphate buffer (pH 7.5) containing 0.1 M NaCl.
over 95% of the pure phages were reported to be recovered using the PEG
precipitation method (Yamamoto and Alberts, 1970).
T7 DNA samples were prepared by phenol extraction (Thomas and
Abelson, 1966) of purified T7 phages.

The purified phage solution was

diluted to an optical density between 5 and 15 in a sterilized test tube
and was shaken (60 rev/min) with equal volume of freshly distilled purified phenol (saturated with a 0.1 M potassium phosphate buffer, pH 7.5,
containing 0.1 M NaCl) for 45 minutes at room temperature.

The tube was

then cooled to 4° C and centrifuged for 5 minutes at 3,000 rpm in an IEC
clinical centrifuge to separate the two phases.

The phenol layer (the

bottom one) was removed with a Pasteur pipet and the DNA solution was
dialyzed exhausively against the original buffer and finally against
0.01 M Tris-HCl buffer (pH 7.8) containing 0.05 M KCl.

This T7 DNA

preparation was used without further purification.
3

H-labeled T7 DNA was isolated from phages grown in the presence

3
of [methyl- H] thymine using thymine-requiring mutant of E. coli B as host
in a M-9 minimal medium (l gNH Cl, 3 g KH Po , 6 g NaHP0 , 4 g glucose and
2 4
4
4
l ml of l M MgS0
thymine/ml.

3

4

in one liter of water) supplemented with

2~g

unlabeled

H-thymine (30 Ci/mmol) was added to the culture l hour

before infection.

The steps for purification of the

particles and the extractions of

3

3

H-labeled phage

H-labeled T7 DNA were identical as

before.
The concentrations of T7 DNA, when designated as DNA-P, are
expressed as equivalents of nucleotide phosphorus, and were determined
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spectrophotometrically using a molar extinction coefficient of 6750
with respect to phosphorus at 260 nm (Richardson, 1966).

The A
/A
260 280

ratio of the purified T7 DNA was 1.91 and the A
;A
ratio was 2.35,
260 230
indicating low protein contamination (Thomas and Abelson, 1966).
rr.3.2.

Preparation of Drug Solution
Working solutions of all anthracyclines were prepared by dis-

solving these compounds in water.

Aqueous solutions of marcellomycin and

musettamycin were prepared by wetting the drug crystals with DMSO,
followed by addition of water.

Drug concentrations were determined

spectrophotometrically using the molar extinction coefficients (Liter•
Mole

-1

•em

-1

) listed in Table 1.

Fresh drug solutions were prepared

for each experiment.
Rifampicin stock solutions were prepared by dissolving 1 mg of
rifampicin into 10 ml of 0.04 M Tris-HCl buffer, pH 7.9.

The stock

solutions were further diluted with the buffer to the desirable concentrantions in each experiment.
II.3.3.

Preparation of Nucleotide Substrates

Unlabeled nucleoside triphosphate solutions were prepared by
dissolving ATP, CTP, GTP and UTP sodium salts (5 mM each) in 0.04 M TrisHCl buffer, pH 7.9.

Radioactively labeled substrates were made by dis-

solving nitrogen-dried (section II.l.)
~Ci/nmole)

3

H-UTP (specific activity 0.02

in unlabeled nucleoside triphosphate solutions.

These sub-

strate preparations were used immediately and no substrate solutions
were used after two weeks of preparation.
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II.3.4.

Preparation of RNA Polymerase Solution
It has been shown that under 37° C temperature, transcription

of T7 DNA by E. coli RNA polymerase takes place primarily at three major
promoter sites at the left end of the genome (Stahl and Chamberlin, 1977).
since under the conditions mentioned above, for every four molecules of
E. coli RNA polymerase only one will bind to the major promoter site on
T7 DNA, 12 molecules of E. coli RNA polymerase are required to saturate
the three type A promoter sites on one molecule of T7 DNA.

Therefore,

unless specified otherwise, a ratio of 12 polymerase molecules per T7 DNA
molecule was used in all the experiments in this study.
RNA polymerase obtained commercially was diluted with buffer
solutions specified in each experiment so that during the assay approximately 1 pg of enzyme proteinwasmixed with 170 uM DNA-P to meet the
molar ratio of 12 to 1.
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II. 4.

Methods

II.4.l.

Determinations of Binding Parameters for Anthracyclines

In order to study the effect of anthracyclines on RNA synthesis
at the molecular level, a quantitative measurement of the drug bound to
T7 DNA under the assay conditions and temperatures must be obtained for
each drug.
The interaction of a large polymeric molecule DNA with small
molecules of drug involves multiple binding sites so that DNA interacts
simultaneously with more than one drug molecule.

Each binding site on

DNA is characterized by an apparent association constant, K
app
[occupied sites]/[unoccupied sites]

[free drug].

If n is the maximum

number of binding sites per DNA nucleotide and rb is the number of
drug molecules bound per DNA nucleotide at a free drug concentration of
[If]

(moles/1), then for one type of site and in the absence of mutual

interaction, the following equation could be obtained.

= Kapp

n - K

app

• r

b

(l)

Scatchardplots (Scatchard, 1949) are constructed by plotting
rb/If vs rb which yield a straight line with a slope of -Kapp
of the apparent association constant (K

app

The values

) and the maximum number of

binding sites per DNA nucleotide (n) can then be obtained from the slopes
and the intercepts.
The spectrophotometric method of Peacocke and Skerett (Peacocke
and Skerett, 1956) was used to determine the apparent binding constant
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and the maximum number of binding sites per DNA nucleotide for each drug
on T7 DNA.

This method is based on the observation that when ligands

bind to nucleic acids, there is a change in the absorption spectrum of
the ligand and this change is dependent upon the concentration of the
nucleic acids.
If the total concentrations of DNA and drug are denoted as [DNA]
and [I ] respectively, then the equation
0

(2)

can be derived in which rb[DNA] is the amount of drug bound to DNA,
(or [Ib]).
[DNA]

If A

0

denotes the absorbance of free drug (when rb = 0, or

= 0, all drug molecules are in free form and A

0

becomes the

absorbance obtained when only drug molecules are present in solution),
~

denotes the absorbance of the bound drug (when all drug molecules are

bound, then [If]= 0 and rb[DNA] = [I

0

]),

and Ax is the absorbance of a

mixture of free and bound drug, then
rb. [DNA]

[If]
A

X

A

=

0

[I ]

+
[I ]

~-

(3)

0

0

If b is the fraction of total drug bound to DNA or
rb• [DNA]

(4)

b
[I ]
0

then from equations (2),

(3) and (4), equation (5) can be derived.

A
b

=

0

- A

X

(5)

A

0

The amount of drug molecules in free form ([If]) can also be obtained
from equations (2) and (4).

Therefore
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In the binding experiments, T7 DNA was mixed with a binding
buffer (0.04 M Tris-HCl, pH 7.9, 0.02 M MgC1 , 0.01 M 2-mercaptoethanol).
2
The concentration of DNA-phosphorus was determined spectrophotometrically
with a Perkin-Elmer 320 spectrophotometer at 260 nrn, using a molecular
extinction coefficient of 6750.

Solutions of increasing DNA to drug

ratios were prepared by adding increasing amounts of drug.

The reaction

mixtures were brought to the same final volume (2 ml) with binding
buffer.

Identical preparations containing equal DNA concentration but

no drug were also prepared and used as reference.
Since only limited amounts of T7 DNA (approximately 1.5 roM) was
obtained from each preparation, the amount of drug (approximately 20
pM)

was chosen so that at the highest DNA to drug ratio, a maximal

change in the visible spectrum due to drug binding to DNA could be
obtained.

One of the helpful features of the Perkin-Elmer 320 spectro-

photometer was that its absorbance scale could be adjusted as desired.
Therefore, the absorbance at A

max

for the solution containing total drug

concentration [I], but in the absence of DNA, could be expanded to full
0

scale, thus providing more accurate readings of the absorbance.
The reaction solutions were incubated for ten minutes at 37° C
for thermal equilibration and the difference absorption spectra were
obtained versus the corresponding reference solutions.
The absorbance of each sample (A ) and total drug concentration
X

in the absence of DNA (A ) were obtained from the recorded spectra at a
0

wavelength chosen so that A

0

totally bound to DNA

(~)

- A was maximum.
X

The absorbance of drug

could be obtained from the absorbance of a
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solution prepared with very high DNA concentration, assuming that all
drug molecules are bound under this condition.

However, since high DNA

concentration required for this purpose caused scattering and introduced
error into the subsequent calculations, the graphic method of Li and
Crothers (Li and Crothers, 1969) was used to obtain
showed that a plot of 1/A -A
0

X

II.4.2.

~

This method

vs 1/[DNA]-[I ] yielded a straight line

--

0

with an intercept on the ordinate equal to
the intercept,

~·

0

l/A -~.

From the value of

may then be calculated.

Nitrocellulose Filter Assay for the Binding of RNA Polymerase
to DNA
Binding of RNA polymerase to DNA was measured using a modifica-

tion of the procedure of Jones and Berg (Jones and Berg, 1966).

RNA

polymerase solution was prepared by diluting commercial enzyme preparation with binding buffer (10 mM Tris, pH 8.0; 10 mM MgC1 ; 50 mM NaCl;
2
10 mM 2-mercaptoethanol; 1 mM EDTA; and 1 mg BSA/ml).
mixture contained 10 pl of

3

The reaction

H-T7 DNA (final concentration of 170 pM

DNA-P) , 80 pl of binding buffer with or without desired amount of inhibitors, and 1 pg of enzyme in 10 ul of enzyme solution so that a molar
ratio of 12 is reached for enzyme and DNA (section II.3.4.).
was initiated by addition of enzyme.

Reaction

After incubation at 37° C for 10

minutes, reactions were diluted to 1.0 ml with binding buffer and filtered
immediately through 24 mm Schleicher and Schuell BA85 nitrocellulose
filter disks with gentle suction (5 em of Hg, which produced a flow
rate of approximately 4 ml/min).

The filter disks were then dried and

the radioactivity determined in toluene containing 0.4% 2,5-diaphenyloxazole in a liquid scientillation counter.

The amount of radioactivity
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collected on the filter disks in the absence of any inhibitors was used
as control.

A minimum amount (-3%) of radioactivity was attributed to

non-specific binding.
rr.4.3.

RNA Polymerase Assays
DNA-dependent RNA polymerase activity was determined by measur-

ing the incorporation of radioactive ribouncleotide substrates into
ribonucleic acid insoluble in trichloroacetic acid (TCA).
Assay reaction mixtures consisting of buffer solution with or
without inhibitors, T7 DNA, RNA polymerase solution, and radioactive
nucleotide substrates were introduced into 12 x 75 mm disposable glass
test tubes.

The exact amount of each component was measured with Pipet-

man adjustable pipets.

The test tubes and all the glasswares used in the

experiments were pre-heated at 180° C for at least 48 hours prior to use
to inactivate any possible contaminating ribounclease activity.

Dispo-

sable plastic gloves were also worn to avoid contamination by human skin
ribonuclease (Rovozzo, 1973).

II.4.3.1.

Assay for RNA Polymerase Activity Under the Influence of
Anthracyclines
In experiments designed to measure the relative inhibitory

potency of all anthracyclines on the overall RNA synthesis in the presence of a constant amount of DNA (170

~M

DNA-P), the enzyme concen-

tration (1 pg/sample) was prepared so as to meet the desired enzyme
to DNA ratio of 12 to 1 (Section II.3.4.).
In these experiments, 35 pl of 2.5 times concentrated buffer A
solution (final concentration: 0.04 M Tris-HCl, pH 7.9; 0.02 M Mgcl ;
2
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o.Ol M 2-mercaptoethanol; 1 mg/ml BSA) was mixed with 20
(final concentration) of T7 DNA and kept at 0°C.

~1

of 170 uM

15 ul of anthracyc-

line solution (or water when used as control) of desired concentration
was added to the mixture and the solution was transferred to a 37° C
bath for 5 minutes.

10 pl of enzyme solution containing 5

buffer (2.5 times its final concentration), 1
protein and deionized water was then added.

~g

~1

of

of commercial enzyme

After 7 minutes of pre-

incubation (i.e., after the formation of RNA polymerase-DNA binary
complex was completed) the RNA synthesis reaction was initiated by the
rapid addition of 10 pl solution containing 5 mM (10 times the final
concentration) each of ATP, GTP, CTP and

3

H-UTP (specific activity:

0.02 pCi/nmol) plus 10 pl of 0.04 M Tris buffer, pH 8.0.

After 90

seconds of incubation at 37° C the reaction was terminated with 1 ml,
freshly prepared ice-cold, 5% trichloroacetic acid solution containing
1 M KCl and 0.05 M of sodium pyrophosphate.
After mixing and standing in ice for 10 minutes the insoluble
material was collected by filtration through a Watman GF/C (2.4 em)
filter disk with gentle suction.

The filter disk was washed with 20

ml of ice cold 5% TCA solution containing 1.0 M KCl and 0.05 M Na P o
2 2 4
followed by 30 ml of 95% ethanol, dried overnight (or at 95° C for 5
minutes) and counted for radioactivity in 10 ml of toluene containing
0.4% 2,5-diphenyloxazole in a Beckman Liquid Scientillation Counter.
The radioactivity absorbed and retained by the filter disks and
the radioactivity trapped within the precipitated components of the
assay mixture was determined from the residual radioactivity of blanks
which did not contain any enzyme.

The blank values were usually less
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than 250 cpm.
Experiments designed to measure the inhibition of ribonucleic
acid chain initiation were conducted as described as above except that
a nucleoside triphosphate solution containing 8-[

32

P]-ATP, CTP, GTP,

3
and [5,6- H]-UTP (Specific activities: l rCi/nmol and 0.02 pCi/nmol,

respectivity) at a concentration of 5 mM for each nucleoside Triphosphate
(ten times the final concentration) was used.
Special procedures for terminating the reaction and for washing
were use d f or

.

exper~ments

.

~nvo

32 P ~ncorporat~on
.
.
.
d
d
l v~ng
.
~n or er to re uce

the high background due to unincorporated radioactivity.

Ractions were

terminated by the addition of O.Sml ice-cold 0.1 M sodium pyrophosphate
solution containing 20 mM ATP and 2 mM UTP and 0.5 ml of ice-cold 10%
trichloracetic acid solution containing l MKCl.

The insoluble material

collected on the filter disks was soaked in 50 ml of ice-cold 5% trichloracetic acid solution containing l M KCl and 0. Ol M sodium pyrophosphate
for l hour, and further soaked in 40 ml of ice-cold 95% ethanol for 20
minutes.

The filter disks were dried as before.
Simultaneous counting of

3

H and

32

P activities were performed

in Beckman Model LS 7500 Liquid Scintillation Counter using a pre-set
condition under which less than 2% activity spill-over between

3

H and

32

could be detacted.

II.4.3.2.

Assay for RNA Polymerase Activity Involving Rifampicin

Rifampicin was used in the experiments designed to measure the
rate constants governing the initiation steps of RNA synthesis.

All of

the experiments involving rifampicin were conducted in buffer B (0.2 M

P
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Tris-HCl, pH 7.9; 0.01 M MgCl ; 0.05 M 2-mercaptoethanol, 5 mg BSA/ml).
2
II.4.3.2.l.

Inactivation of RNA Polymerase-DNA Complex by Rifampicin

In experiments designed to study the kinetics of rifampicin
inactivation of DNA-RNA polymerase complex, the DNA-RNA polymerase
complexes were formed as described previously (Section II.3.4.l.) in
the presence or absence of anthracyclines.

After 7 minutes of incuba-

tion at 37° C, 10 pl of rifampicin solution with a final concentration
of 0.312 pg/ml was added.

Incubation was continued for a designated

period of time and the RNA synthesis reaction was initiated by adding
10 pl of radioactively labeled substrates.

The reaction was terminated

90 seconds later and the product was processed as described previously
(Section II.4.3.l.).

Under these conditions, the amount of RNA formed

should be a direct measure of the amount of active RNA polymerase bound
to DNA complexes.

The number of complexes at t

=0

is experimentally

defined as the amount of RNA synthesis obtained in 90 seconds when both
rifampicin and the four ribonucleoside triphosphates were added to the
complexes at the same time.

II.4.3.2.2.

Assay for the Rate of RNA Synthesis as a Function of
Rifampicin Concentration

In experiments designed to measure the rate of RNA synthesis as
a function of rifampicin concentration, the enzyme-DNA complexes in the
presence or absence of anthracyclines were prepared as described previously (Section II.4.3.l.).

RNA synthesis was initiated by the addi-

tion of 20 pl of a substrate-rifampicin mixture (10 pl substrate, 10 pl
rifampicin in 0.04 Tris-HCl, pH 7.9) prepared so as to give the desired
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final rifampicin concentrations.

The reaction was then terminated and

the product processed as described previously (Section II.4.3.l.).

II.4.3.2.3.

Assay for the Rate of RNA Synthesis as a Function of Preincubation Time

In experiments designed to measure the rate of RNA synthesis as
a function of pre-incubation time, the drug-DNA complexes were prepared
as described previously (Section II.4.3.l.) but at 0° C.

After addition

of the desired amount of enzyme, the reaction mixture was transferred to
a water bath at 37° c for the appropriate period of time (i.e., for
various pre-incubation times) and RNA synthesis was initiated by the
addition of substrate-rifampicin mixtures.

The termination and product

processing steps were identical as described previously (Section II.4.3.l.)

II.4.3.2.4.

Assay for the Rate of RNA Synthesis as a Function of Preincubation Temperature

In experiments designed to measure the rate of RNA synthesis as
a function of pre-incubation temperature, the drug-enzyme-DNA complexes
were prepared as described previously (Section II.4.3.l.) but at 0°

c.

Then the complexes were transferred to a water bath at different temperatures for pre-incubation for 7 minutes.

The RNA synthesis reaction was

initiated at 37° C and the subsequent reaction and product were treated
as described previously (Section II.4.3.l.).
The background values for experiments involving rifampicin were
determined from reaction mixtures prepared identically with each experiment but in the absence of the enzyme.
less than 750 cpm.

These values were usually

Higher background vales (from 750 to 1000 cpm) were
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obtained when daunomycin was present together with rifampicin.

The

reason for this higher background is not known but it may be attributable
to interaction among rifampicin, daunomycin and the radioactive substrates.

CHAPTER III

EXPERIMENTAL RESULTS

III.l.

The Binding of Anthracyclines to T7 DNA

In order to study the effects of anthracyclines on RNA synthesis,
the binding parameters for each drug on DNA must be obtained under ionic
and temperature conditions identical to those employed in the assays for
RNA polymerase activities.
Binding experiments for each anthracycline analog were conducted
as described under Methods (Section II.4.1.).

Preliminary results indi-

cated that BSA had no effect on the extent of binding and in subsequent
measurements BSA was omitted from the buffer.

In these measurements,

the concentration of the drug was kept constant at approximately 20 pM,
while the concentration of T7 DNA was varied.
Typical spectrophotometric titrations of anthracyclines with DNA
are shown in Figure 8 which demonstrates the effect of increasing amount
of DNA on the absorption spectra of anthracyclines.

Under the specified

conditions, free daunomycin exhibits three absorption maxima at 502, 535
and 575 nm as shown in Figure Sa.

This significant change in absorption

spectrum from that mentioned in Section I.2.7.1. is due to the presence
of MgC1 •
2

2
Although high concentration of Mg + was reported to release

anthracyclines form the drug-DNA complex (Calendi et al., 1965) the
concentrrion of MgCl

2

present in this study is significantly lower.

Upon addition of T7 DNA, the intensity at all absorption maxima
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Figure Sa.

Visible Absorption Spectra for daunomycin-T7 DNA Complex

Experiments were conducted with a Perkin-Elmer 320 spectrophotometer.

18.8

~M

of daunomycin in binding buffer (0.04 M Tris-HCl, pH

7.9, 0.02 M MgC1 , 0.01 M 2-mercaptoethanol) was mixed with increasing
2
amount of T7 DNA as described in Methods (Section II.4.1.).
centrations of T7 DNA are a) 0
e) 204 pM, f) 243

~M,

~M,

b) 88

g) 288 pM, h) 390

~M,

c) 114

~M,

The con-

d) 168

~M,

~M.

Measurements were carried out at 37°

c.

A minimum of three

determinations of binding parameters were made for each anthracyclineDNA combination.

Each binding determination consisted a minimum of 9

different DNA concentrations in duplicate samples.
the data is shown.

Only a portion of
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Visible Absorption Spectra for Aclacinomycin-T7 DNA Complex

20 pM of aclacinomycin solution in binding buffer was mixed with
increasing amount of T7 DNA as described in Figure Sa.
of DNA are a) 0 pM, b) 48

~M,

The concentrations

c) 96 pM, d) 175 pM, e) 242 pM, f) 390 pM.
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decreases and the two maxima at longer wavelength tend to disappear more
quickly than the one at 502 nm, which became predominant at the highest
DNA to drug ratio employed.

The largest changes in absorbance were ob-

served at 535 and 575 nrn and the absorbances at these wavelengths were
used in the calculation of binding parameters.
Only one clear isosbestic point is observed for daunomycin.

If

there had been a DNA concentration range in which the spectra of the
drug-DNA complex had exhibited an isosbestic point while in another DNA
concentration range no isosbestic point had been observed, this would
have been a clear indication of the presence of more than two spectral
species.

This is not the case for daunomycin, therefore the spectra of

daunomycin were evaluated under the assumption that only two spectral
species are present in the solutions; i.e.,the free drug form and the
DNA-bound drug form.

This assumption is further supported by the find-

ings that the intrinsic association constants determined from the spectral changes at 535 and 575 nrn are in good agreement with one another.
The absorption spectra for the rest of the anthracycline analogs, with
the exception of aclacinomycin, exhibit a similar pattern.
Figure 8b shows the absorption spectra of aclacinomycin under
the same experimental condition.

Like that of daunomycin, the inten-

sity of the absorption maximum decreases upon addition of DNA.

The ab-

sorption maximum of aclacinomycin is also shifted from 515 nm at zero
DNA to drug ratio to 450 nm at maximal DNA to drug ratio.
point is presnet at 460 nrn.

An isosbestic

As is the case with daunomycin, the presence

of an isosbestic point indicates that only two spectral species of aclacinomycin are present; the DNA-bound drug and the free drug.
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The largest changes of absorbance were obtained at 517 nm and
therefore, absorbances at this wavelength were used in calculating the
binding parameters for this drug.
The values for rb (the number of drug molecules bound per DNA
nucleotide) and If (the concentration of free drug) for each anthracycline
analogs studied were calculated according to equations (4) and (6) respectively.

The association constant (k

app

) and the maximum number of

binding sites per DNA nucleotide (n) for each drug were obtained from
the slopes and intercepts of Scatchard plots constructed according to
equation (1).
The Scatchard plots for each anthracycline studied are shown in
Figures 9a and 9b and the calculated values of k

app

and n for each drug

are listed in Table l.
In Figure 9a, at lower DNA to drug ratio, the Scatchard plots
shown deviations from the straight line and therefore, the intercept on
the abscissa were made by extrapolations of the linear portions of the
plots (Chambon, 1975).

The deviations indicate the existence of two dis-

tinct processes of unequal strength for the binding of anthracyclines to
DNA.

At low DNA to drug ratio, the drugs are able to bind to DNA through

electrostatic interactions at secondary binding sites in addition to the
intercalative mode of binding which occurs at primary binding sites when
the DNA to drug ratio is high.

This interpretation is consistent with

that of previous studies based on Calf thymus DNA (Zunino et al., 1972)
and model building (Section I.2.7.2.).

The absence of deviation for the

aclacinomycin group of drugs in Figure 9b indicates that no significant
amount of secondary binding is present.

This observation is consistent

79

Figure 9.

Scatchard Plots for Some Anthracyclines

The Scatchard variables of rb (the number of ligands bound per
nucleotide) and If (the molar concentration of free drug) were calculated
from the data obtained from spectrophotometric titrations (Figure 8) according to the method of Peacocke and Skerett, 1956.
a) 4-demethoxydaunomycin
b) aclacinomycin

-e-,

-e-,

daunomycin -•-, carminomycin

marcellomycin -•-, musettamycin

-o-.

-o-.

The lines were drawn using the method of linear regression with
the aid of Apple II computer.

Each value represents the mean ± the

standard deviation of three experiments in duplicate samples.
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Table I
Binding Parameters for DNA Interaction with
Anthracyclines

Anthracyclines

n

Group I:
daunomycin

3.63 ± 0.21

0.070 ± 0.050

4-demethoxydaunomycin

5.28 ± 0.36

0.070 ± 0.002

carminomycin

1.31 ± 0.16

0.065 ± 0.001

ac1acinomycin

8.92 ± 0.54

0.100 ± 0.007

marcellomycin

6.84 ± 0.61

0.100 ± 0.005

musettamycin

5.59 ± 0.26

0.110 ± 0.005

Group II:

Binding parameters were determined from plots of rb/If
versus rb, where K
(the apparent association constant) is the negative
app
slope and n (the apparent number of binding sites per nucleotide) is the
intercept on the rb-axis of the corresponding Scatchard plot. Each
value represents the mean ± the standard deviation.
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with the data obtained from fluoresence quenching studies which also
showed only one type of binding between marcellomycin and various type
of DNA (DuVernay et al., 1979a).

As mentioned previously (Section

I.2.7.2.) any modification of the amino group would reduce the secondary
binding.

In the case of group II anthracycline, this is probably due to

the inability of the masked amino group to either develop a positive
charge to form secondary binding, or, even if the charge can develop,
its effect is weakened by the presence of the di-methyl substitution.
In any event, the secondary binding is insignificant in the binding of
group II anthracyclines to DNA.
In the subsequent study of the inhibition of RNA synthesis by
anthracycline analogs it is essential to realize that the true inhibitor of the RNA synthesis system is the DNA-bound form of the drug
(Section III.3.2.).

Since from the results of the binding studies

anthracyclines may bind to DNA in two different forms; i.e., intercalation and secondary binding, their effect on RNA synthesis may
become very complicated to study.

Therefore in order to understand

the mechanism of inhibition of RNA synthesis by each DNA-bound anthracycline molecule in terms of intercalation alone, one has to make sure
that intercalation is the only mode of interaction between the drug
and DNA.

This can be achieved by limiting the number of DNA-bound

drug molecules (rb) under 0.05 per DNA nucleotide, which, according
to the Scatchard plot, should eliminate the possibility of secondary
binding.

Under this condition, the resulting inhibitory effect of

anthracyclines in terms of DNA binding can only be attributable to
intercalation alone.
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There is approximately a 3-fold decrease in the binding constants
and the number of binding sites when the data from the present study
are compared with that reported in the literature (Zunino et al., 1980;
Rich et al., 1981).

This apparent discrepancy may be explained by the

2
presence of Mg +, which has been reported to reduce the normal binding
of daunomycin to DNA (DiMarco et al., 1972; Bhuyan et al., 1965).
Based on the shapes of the Scatchard plots, the differences in
binding constants and the number of drug molecules bound per DNA nucleotide, the anthracyclines studied in this project could be categorized
into two groups; i.e.,

(I) the daunomycin group, which includes daunomycin,

4-demethoxydaunomycin and carminomycin and (II) the aclacinomycin group,
which includes aclacinomycin, marcellomycin and musettamycin.

This dis-

tinction is also correlated to the basic structure of the anthracyclines;
i.e., those without extra sugar groups on the daunosamine (the daunomycin
group), and those with one or more sugar residues attached to rhodosamine
(the aclacinomycin group).
Generally speaking, group II anthracycline molecules bind to T7
DNA with greater affinity and more of them can bind per DNA nucleotide.
The increase of affinities of anthracyclines to DNA has been attributed
to the presence of C-10 subsitution and extra residues on the glycosidic
side chain (DuVernay et al., 1979a,b) despite the fact that the amino
group on the primary sugar residue has been masked by two bulky methyl
groups.

The effects of other substitutions (i.e., at C-1, C-11, and

C-13) are not clear at this moment.
Differences in binding parameters are also noted among group I
anthracyclines.

The calculated binding constants for daunomycin and
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4-demethoxydaunomycin are found to be 3.63 x 10
respectively.

6

M-l and 5.28 x 10

6

M-l

This result shows a higher DNA binding ability for 4-

demethoxydaunomycin and is in disagreement with the binding constant
obtained previously on Calf thymus DNA (Zunino et al., 1976) which suggested a stronger binding for daunomycin.

However, the present result

is consistent with the expectation based on the structural analysis that
4-demethoxydaunomycin should have a higher affinity for DNA due to the
absence of the

III.2.

bulky methoxy group on C-4 of daunomycin (see page 48).

Assays for the Most Appropriate Conditions to be Used in Subsequent Experiments

In order to establish the assay conditions for the inhibition
studies, the

RNA synthesis by DNA-dependent RNA polymerase as a function

of reaction time was studied using T7 DNA as template.

The amount of RNA

synthesized was plotted against the reaction time and the results are
shown in Figure 10.
From Figure 10 it is evident that for the first 10 minutes, RNA
synthesis is linear with respect to incubation time, then it slows down
considerably and finally reaches a plateau at around 60 minutes.

The rate

of the reaction follows roughly first order kinetics as can be seen from
the linear plot in Figure 11.

A reaction time of 90 seconds was used in

all subsequent assays to eliminate reinitiation (see Methods), and this
reaction time falls well within the limit of 10 minutes beyond which substrate depletion may occur.
The effect of template concentration on RNA synthesis was also
studied and the results are presented in Figure 12.

The reaction seems

to follow Michaelis-Menton kinetics and the Lineweaver-Burk plot is pre-
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Figure 10.

The Kinetics of RNA Synthesis

170 pM of T7 DNA was pre-incubated at 37° C with 1 pg of RNA
polymerase for 8 minutes.
0.5 mM of

3

The initation was started by the addition of

H-labeled nucleotide substrate.

The reaction was terminated

according to the time specified and the radioactive product was collected and processed as described in the Methods (Section II.4.3.1.).
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First Order Plot of the Effect of Reaction Time on RNA
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Figure 12.

The Effect of Template Concentration on RNA Synthesis.

Various amount of T7 DNA were mixed with RNA polymerase for
8 minutes.
of

3

The reaction was then initiated by rapid addition of 5 mM

H-labeled substrates and terminated 90 seconds later.

RNA poly-

merase activity is expressed as radioactivity retained on filter papers.
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sented in Figure 13.

It is also apparent from Figure 12 that the maxi-

mum amount or incorporation of radioactivity occurs at 170

~M

of DNA-P

when 5 mM (initial concentration) of labeled nucleotide solution is used.
Therefore, for subsequent experiments DNA concentration of 170

~M

and an

enzyme to DNA molar ratio of 12 were used to ensure the highest amount
of incorporation of radioactive materials under the specific
nucleotide concentration.

3

H-labeled
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Figure 13.

Linewaver-Burk Plot of RNA Polymerase Activity as A Function

of Template Concentration
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III.3.

III.3.1.

The Inhibition of RNA Polymerase Activity By Anthracyclines

The Relative Potency of Anthracyclines on the Overall Inhibition of RNA Synthesis
The relative inhibitory activity of anthracyclines were studied

by determining the level of RNA polymerase activities in the presence
and absence of the drugs.

Increasing amounts of drug were mixed with

constant amounts of DNA, enzyme and nucleotide substrates and assayed
for RNA polymerase activity, which was expressed as the amount of radioactive materials incorporated after a specific reaction time.

The inhi-

bitory activity of each drug was expressed as the percent residual enzyme
activity determined by the radioactive materials synthesized, under the
influence of increasing amount of anthracyclines, over that in the absence of drug.
In Figure 14, percent radioactivities are plotted vs the total
added drug to DNA-P ratio.

Clearly this ratio of drug over DNA-P does

not provide any information as to the amount of drug that is actually
bound to DNA.
From Figure 14 the effectiveness of each anthracycline in the
inhibition of the overall RNA synthesis can be obtained.

The added drug

to DNA-P ratios which cause 50% inhibition of RNA synthesis for the different anthracyclines are listed in Table II.
In general, the ability of each anthracycline to inhibit RNA synthesis rises sharply with increasing amounts of added drug until roughly
a 0.1 added drug to DNA ratio is reached.

Beyond this point the increase

in inhibition slows down and finally reaches a maximum.

However, even

though the inhibitory curves for all the drugs studied have a similar
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Figure 14.

The Overall Inhibitory Effectiveness of Anthracycline Analogs

on T7 RNA Synthesis

Enzyme-template binary complexes were formed by mixing 1 pg of
RNA polymerase with 170 uM of DNA in the presence of desired amount of
daunomycin

(e) ,

4-demethoxydaunomycin (

0) ,

carminomycin ( •),

aclacinomycin ( t:..) , marcellomycin ( o) , and musettamycin ( • ) at 37° C,
so that the added drug to DNA ratios were maintained within the range of
0 to 0.4.

RNA synthesis was then initiated with the addition of ribonu-

cleotide substrate (0.5 mM each of ATP, GTP, CTP and
and terminated 90 seconds later with 5% TCA.

3
H-UTP, 0.02 pCi/nmol)

The acid insoluble RNA pro-

duct was collected on a filter paper and counted for radioactivity in a
liquid scintillation counter.

The amount of radioactivity obtained at

zero drug concentration was used as 100% RNA polymerase activity.
Each value represents the mean ± the standard deviation of six experiments.
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Table II

Comparison of the Inhibitory Effectiveness of Some Anthracyclines towards
RNA Synthesis

Anthracycline
analogs

Added drug/DNA ratio
resulting in 50% inhibition

Group I:
daunomycin

0.078

13.3

4-demethoxydaunomycin

0.058

9.9

carminomycin

O.llO

18.7

aclacinomycin

0.030

5.1

marcellomycin

0.033

5.6

musettamycin

0.043

7.3

Group II:
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shape, they may be separated into two groups according to the structure
of the compounds mentioned before.
Important quantitative differences in the inhibitory behavior
of anthracyclines are evident from Table II.
ed drug to DNA (i.e., Ic

50

For the same ratio of add-

), the aclacinomycin group is generally more

effective (twice as effective on the average) than the daunomycin group.
This higher effectiveness against RNA synthesis for group II anthracyclines is consistent with the result from in vitro studies with tumor
cells (Crooke et al., 1977).
Results from the binding study (Table I) show that more drug
molecules from group II anthracyclines can bind per unit DNA than group
I drugs.

This is indicated by the smaller size of binding sites (1/n,

with n being the number of binding sites per unit DNA) required for group
II anthracyclines.
greater affinity.

In addition, group II drugs can bind to DNA with
Since previous reports indicated that RNA synthesis

was directly related to the amount of DNA-RNA polymerase stable complexes
formed (Hinkle and Chamberlin, 1972 a-d), it is logical that when identical
amount of drugs from group I and group II anthracyclines are added to a
constant amount of DNA, more drug molecules from group II can bind to DNA
with greater affinities and thus inhibit the formation of the DNA-RNA
polymerase complex to a greater extent.
The relative effectiveness of anthracyclines toward RNA synthesis
inhibition within each group can also be evaluated in terms of their binding parameters.

For example, the differences in the extent of inhibition

between members of group I anthracyclines follow closely with their binding affinities.

Specifically, in the case of 4-demethoxydaunomycin, the
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removal of the methoxy group on C-4 increases both the binding and inhibitory effectiveness of the drug.

From the x-ray diffraction study of

the crystals of the intercalated complex of daunomycin and DNA (Rich
et al., 1981) it is evident that ring A which contains the methoxy group
penetrates completely through the base pairs and hangs out on the other
side into the major groove.

Removal of this bulky methoxy group may aid

the penetrating process, thereby stabilize the intercalated complex.

On

this basis one might expect that carminomycin also should be a better
binding drug than daunomycin.

However, carminomycin was found to bind

less strongly to DNA and to inhibit RNA synthesis less than daunomycin.
Similar results have also been obtained in the comparative study of DNA
binding between carminomycin and adriamycin (DuVernay et al., 1980).

It

is possible that inter- or intra-molecular hydrogen bonding involving the
C-4 hydroxyl group of carminomycin might be present which could interfere
with the intercalation of the aglycone of this compound.
No significant differences in either the binding effectiveness
or the RNA synthesis inhibitory effect were found among members of group
II anthracycline probably because no significant differences are present
in the substitution on the aglycone of these drugs.
In any event, there seems to be a structural-activity relationship among the two groups of anthracyclines studied.

Substitutions on

C-10 and C-4' provide group II anthracyclines with better binding affinities to DNA and therefore stronger inhibitory effect on overall RNA
synthesis over that of group I drugs.

Furthermore, C-4 substitutions for

group I anthracyclines play an important role in changing anthracycline
binding to DNA and the ability to inhibit RNA synthesis.
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III.3.2.

The Effect of DNA-Bound Anthracyclines on RNA Synthesis

Daunomycin has been shown to inhibit RNA synthesis by reducing
the availability of DNA template for binding RNA polymerase.

This re-

duced availability is a consequence of daunomycin intercalating to DNA
(Mizuno et al., 1975). Daunomycin has no effect on the activity of RNA
polymerase per se (Zunino, et al., 1974).

Therefore the form of the drug

in solution which is active in the inhibition of RNA synthesis is the
DNA-bound form, and Figure 15, which is a plot of the RNA polymerase
activity vs DNA-bound drug concentration (i.e., rb, Section II.4.1.), is
essential for providing information regarding differences on the inhibition of RNA synthesis by anthracycline on a molecular level.
The corresponding rb value for each added drug to DNA ratio in
Figure 14 was obtained using equations (1) and (2) and subsequently
Figure 14 was converted into Figure 15.

In this figure, the relative

effectiveness of each anthracycline analog expressed in terms of DNA-bound
concentration (rb) toward inhibition of RNA synthesis, are compared.
The rb values for each anthracycline analog which cause 50% RNA inhibition
are listed in Table III.
The results in Figure 15 appear strikingly different from those
shown in Figure 14.

Specifically, on the basis of equal amount of drug

molecules bound to T7 DNA, the relative inhibitory effectiveness of group
I and group II anthracyclines are reversed, i.e., the members of the daunomycin group are more effective in inhibiting RNA synthesis than the members of the aclacinomycin group.

This finding indicates that identical

numbers of bom1d drug molecules per unit DNA have different inhibitory
effects on the ability of RNA polymerase to utilize DNA as template for
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Figure 15.

The Inhibiroty Effectiveness of DNA-Bound Anthracyclines

Toward RNA synthesis

RNA polymerase activity is plotted verses the number of drug
molecules bound to each DNA nucleotide (rb).
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Table III

Comparison of the Inhibotory Abilities of Anthracyclines based on the
Concentration of DNA-bound Drug

Anthracyclines

~

at which 50% inhibition is observed

Group I:
daunomycin

0.015

4-demethoxydaunomycin

0.011

carminomycin

0.016

Group II:
aclacinomycin

0.020

marcellomycin

0.022

musettamycin

0.024
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RNA synthesis.

Consequently, the inhibitory effectiveness of these

anthracyclines is determined not only by the affinity of each drug to DNA
but may also by the specific structure of the drug molecules from each
group of anthracyclines.
Besides the binding of RNA polymerase to DNA, another area which
directly affects RNA synthesis is the mechanism by which RNA polymerase
carried out its catalytic functions.

The mechanism of DNA synthesis has

been shown to be sensitive to the structures of the intercalated anthracyclines (Goodman and Lee, 1977; Section I.2.8.2.).

It is likely, there-

fore, that different structures of the intercalated anthracycline analogs
might also affect the mechanism of RNA synthesis to a different extent.
At this point it should be noted that the concentration of anthracyclines at which the inhibition of

~~A

synthesis is studied (i.e., rb<

0.035) is far less than the level for secondary binding to occur (rb >
0.05).

Therefore the inhibitory effect of the drug studied is not due

to the result of secondary binding.

III.3.3.

_The Effect of Template Concentration on the Overall RNA
Synthesis Inhibition By Anthracycline Analogs

Previous studies have demonstrated that daunomycin inhibits RNA
synthesis competitively with the template and the inhibition can be overcome by re-addition of the template (Zunino et al., 1974).

In the present

study, RNA synthesis under the influence of anthracyclines was studied by
determining the level of RNA polymerase activity as a function of template
concentration in the presence and absence of a constant amount of various
inhibitors.

Inhibitor concentrations were chosen so as to cause 50% inhi-

bition of overall RNA synthesis as determined in Section III.3.1.
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The results from two representative members of group I anthracyclines (daunomycin and carminomycin) and one from group II anthracyclines
(aclacinomycin) are presented as Lineweaver-Burk plots in Figure 16a, b
and c.

The lines for the inhibited and un-inhibited reactions cross over

on the coordinate indicating competitive inhibition for all the anthracycline analogs studied.

Clearly the inhibitory effects of each drug

can be completely abolished when the concentration of DNA is in large
excess relative to that of the inhibitor.

In addition, pre-incubation

of the drugs with RNA polymerase was found to have no effect on the
inhibition.
It is also apparent that the Lineweaver-Burk plots for the inhibited reactions deviate from linearity.
nounced at higher drug to DNA ratios.
to

the

This deviation is more pro-

This surprising behavior is due

fact that in the presence of a constant amount of intercalators,

the increase in DNA concentration causes a gradual decrease in rb (the
number of DNA bound drug molecules per DNA nucleotide) as indicated by
equation (7)

(Section III.3.2.).

Since the actual concentration of the

inhibitors should be expressed in terms of r

b

rather than [I ] , a gradual
0

decrease in rb also gradually reduces the slope of the inhibited plot in
Figure 16, and results in curvilinearity.

A similar observation has been

reported in the study of the interactions between phenanthridines and
DNA (Aktipis and Panayotatos, 1981).
In any event, this result demonstrates that anthracyclines studied
in this project competitively inhibit RNA synthesis and is consistent
with the proposal that the inhibition of RNA synthesis by anthracycline
is primarily due to the inactivation of the template (Zunino et al., 1974).
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Figure 16.

The Effect of Template Concentration on RNA Synthesis

The amount of RNA synthesized was measured in the absence of
intercalators (e), or in the presence (O) of (a) 13.3
(b) 18.7

~M

of carminomycin, and (c) 5.1

~M

~M

of daunomycin,

of aclacinomycin.
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III.3.4.

Mechanisms of Inhibition of RNA Synthesis By Anthracycline Analogs

The results presented in the preceding pages suggest that the
mechanisms by which the two groups of anthracycline analogs inhibit RNA
synthesis may be different despite the fact that they all inhibit RNA
synthesis competitively.

Previous reports on the mechanism of RNA syn-

thesis inhibition by daunomycin have suggested that daunomycin inhibits
RNA synthesis initiation without significantly affecting elongation due
to the relatively rapid dissociation of the drug from DNA (Schellinx et
al., 1979).

However, this conclusion is clearly in contradiction with

a previous report in which daunomycin was found to affect the elognation
of RNA chains (Zunino et al., 1974).

Since the initiation of RNA synthe-

sis from T7 DNA by E. coli RNA polymerase has been studied thoroughly and
the different steps in the events prior to the formation of the first
phosphodiester bond have been elucidated (Section I.3.5.), it is of interest to examine the effect (if any) of each anthracycline analog on the
events that precede the formation of the first phosphodiester bond as well
as its effect on chain elongation.

III.3.4.l.

The Effect of Anthracycline Analogs on the Formation of DNARNA Polymerase Complex

Conflicting results have been reported concerning the ability of
daunomycin to inhibit the formation of DNA-RNA polymerase stable binary
complexes which are necessary prior to the formation of the first phosphodiester bond (Section I.2.8.l.).

In this study the effect of anthra-

cyclines on the formation of DNA-RNA polymerase binary complexes were
examined by measuring the radioactivity retained on filter paper using a
method devised by Jones and Berg in 1966.

This method is based on the
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observation that when a buffered solution containing DNA and RNA polyrnerase is subjected to filtering, only the DNA-RNA polymerase binary cornplexes are retained on the filter if a controlled rate of filteration is
used.

Any unassociated molecules of either free DNA or RNA polymerase

are filtered through.

In the present study, the amounts of

3

H-T7 DNA

and RNA polymerase were kept constant while increasing amounts of various
inhibitors were added.

The experimental details are presented in the

Methods (Section II.4.2.)
Figure 17 shows the results of the effect of anthracyclines on
the formation of DNA-RNA polymerase binary complexes.

It is evident that

as the amounts of inhibitors increase fewer DNA-RNA polymerase complexes
are formed as indicated by the decreasing amount of radioactivity retained on the filters.

The shape of the inhibitory curves is similar for

all the anthracycline analogs studied.

However, with the aclacinornycin

group, an almost linear relationship is noted between the effectiveness
of the members of the group in dissociating the enzyme-DNA complex and
drug concentration up to low concentrations of the drug.

The inhibition

of the binary complex formation by members of the daunomycin group, on
the other hand is relatively low until an added drug to DNA ratio of
about 0.04 is reached.

Beyond this point inhibition increases fairly

rapidly with increasing amount of added drug.

However, the increase is

not as rapid as that noted for the aclacinornycin group.
The added drug to DNA ratio for each drug at which only 50% of
the binary complex is formed are listed in Table IV.

Comparison of the

data in Table II and Table IV indicates that within group II anthracyclines
the relative inhibitory effect of each drug against complex formation
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Figure 17.

The Effectiveness of Anthracyclines on the Dissociation of

the DNA-RNA Polymerase Binary Complex:

Amount of Complex Determined by

the Nitrocellulose Filter Assay

10

~1,

170

~M

of

3

H-T7 DNA in 80 ul binding buffer with or without

desired amount of rifampicin or anthracyclines, was mixed with 10 pl
(containing l

~g)

of RNA polymerase.

After incubating at 37° C for 10

minutes, the mixture was diluted to 1.0 ml with binding buffer and filtered through a nitrocellulose filter paper.

The radioactivity collected

on the filter is proportional to the amount of DNA-RNA polymerase binary
complexes formed.
Results obtained:

without anthracycline but in the presence of

rifampicin (X) ; in the presence of daunomycin ( •); 4-demethoxydaunomycin ( 0); carminomycin ( • ) ; aclacinomycin ( A); marcellomycin ( o ) ;
musettamycin ( •).

Each value represents the mean± the standard

deviation of four experiments.

114

Rifampicin, IJ9/ml

70

c::

.Q
..~

...E

0

u.
)(

~

~

E
0

(.)
~

30

+
20

.02

.04

.06

.08

.10

.12

.14

.16

Added Drug to DNA Ratio

.18

.20

.22

115

Table IV

Effect of Anthracyclines on the Formation of
the DNA-RNA Polymerase Complex

Anthracyclines

added drug to DNA ratio
which causes 50% inhibition

Group I:
daunomycin

0.096

4-demethoxydaunomycin

0.085

carminomycin

0.140

Group II:
aclacinomycin

0.035

marcellomycin

0.035

musettamycin

0.045
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closely parallel that of RNA synthesis inhibition.

This observation

seems to suggest that the overall RNA synthesis inhibition by group II
anthracyclines is a direct result of their abilities to inhibit templateenzyme complex formation.

In contrast, the RNA synthesis inhibition by

group I anthracyclines can only be partially explained by their complex
inhibition abilities.

For example, the drug to DNA ratios for daunomycin

which cause 50% of inhibition in RNA synthesis and enzyme-template complex
formation are 0.078 and 0.096 respectively.

Other factor must also exist

to contribute to the total RNA synthesis inhibition abilities of group I
anthracyclines in addition to their inhibition of the DNA-enzyme complex
formation.
This study also shows that rifampicin, which attacks RNA polymerase, does not prevent RNA polymerase from binding to T7 DNA.

This is

indicated by the fact that 100% radioactivity was recovered even in the
presence of the highest rifampicin concentration tested (1.25 ug/ml) in
the experiment.

Other experiments (data not shown) carried out in the

presence of rifampicin with and without RNA polymerase show that only DNAenzyme binary complexes are retained on the filters, DNA with or without
rifampicin is filtered through.

III.3.4.2.

The Effect of Anthracycline Analogs on Events Prior to the
Formation of the First Phosphodiester Bond

As described in Figure 5, the interaction of T7 DNA and E. coli
RNA polymerase leading to the formation of the first phosphodiester bond
consists of three sequential events:

(1) reversible, weak binding of

RNA polymerase to T7 DNA at random sites,

(2) enzyme attachment to a

site at or near a specific promoter site to form the I complex,

(3)
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transformation of the I complex to a highly stable RS complex, from
which a new complex (the OP complex) can be formed with the formation
of the first phosphodiester bond.
In the following experiments, the rates of each of these two
complex transformations were studied under the influence of anthracycline analogs.
III.3.4.2.l.

The Rate of RS to OP Complex Transformation

The antibiotic rifampicin, which has been found to inhibit RNA
synthesis initiation without affecting elongation (Mangel and Chamberlin,
l974c), is used in the assay for studying the rate of RS to OP complex
transformation.

In addition, rifampicin does not block the formation

of RS complex, and does not increase the rate of dissociation of this
complex (Section III.3.4.l.).

In fact, the ribonucleoside triphosphate

substrates are in competition with rifampicin so that once the first
phosphodiester bond is formed, the RS complex transforms into OP complex
and becomes insensitive to rifampicin (Mangel and Chamberlin, l974c).
The rate of rifampicin attack on the highly stable T7 DNA-RNA
polymerase holoenzyme complex (RS complex) has been shown to obey second order kinetics (Hinkle et al., l972d).

Therefore, if RNA polymerase-

T7 DNA binary complexes are formed in the presence of anthracyclines and
then challenged simultaneously with a mixture of rifampicin and the four
ribonucleoside triphosphates, two competing reactions

(equations 7 and 8

below) would take place:
(l)

Inactivation by rifampicin:
C

+

R

_______k_2______~~

cr

(7)
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(2)

RNA chain initiation:
k*

C + nXTP

C*

(8)

In these equations C represents the concentration of RNA polymerase
r

holoenzyme-T7 DNA binary complex:

C

represents the concentration of the

binary complexes inactivated by rifampicin and consequently unable to
initiate a RNA chain; C* represents the binary complexes which have
initiated an RNA chain and are therefore insensitive to rifampicin;
k

2

is the second order rate constant for rifampicin attack on RNA poly-

merase-T7 complexes, and k* is an apparent first order rate constant for
RNA chain initiation at a particular concentration of ribouncleoside
triphosphates.
With the assumptions that the binding of rifampicin to holoenzyme
in the binary complex is irreversible; that RNA chain initiation by the
binary complexes is irreversible and that during the assay, concentration
of rifampicin and the ribonucleoside triphosphates remain constant, and
with the use of the conservation equation:

c0

(9)

(where C is the concentration of binary complexes at t
a

=

0,) the follow-

ing relationship can be derived from equations (7) to (9):
[R]

(10)
C*

k*

The second order rate constant for rifampicin attack on holoenzymeT7 DNA complexes (k ) is 3.5 x 10
2
only an assay for measuring C

0

3

-1 -1

M

S

(Hinkle et al., 1972d); thus,

and C* is required to determine the apparent
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first order rate constant for RNA chain initiation (k*).

With this assay,

c is experimentally defined as the amount of RNA synthesized in 90 seconds
0

(Second II.4.3.2.l.) in the absence of rifampicin, and C* is the amount of
RNA synthesized under identical conditions but in the presence of rifampicin.
To calculate the rate of RNA chain initiation, equation (10) can
be transposed utilized equation (9) to yield equation (11),

---------- + 1
C*

(11)

k*

where C /C* represents the reciprocal of % RNA polymerase activity.
0

At

various concentrations of rifampicin, a graph of the reciprocal of % RNA
polymerase activity vs the rifampicin concentration should result in a
straight line with a characteristic slope.

The slope should be equal to

the rate of the second-order rate constant of rifampicin attack on the
binary complex (RS) over the rate constant of the transformation of the
RS complex to the rifampicin-insensitive ternary complex (OP), or k /k*.
2
In order to study the effect of anthracycline analogs on the
rate of RS to OP complex transformation, identical assays can be performed in the presence and absence of anthracyclines.

If anthracyclines

change the rate of RNA synthesis initiation (i.e., the transformation of
RS to OP complex) , the slope of the C /C* vs [R] plot should be different
0

assuming that the rifampicin attack on RNA polymerase is not affected by
the presence of the intercalating anthracyclines.
Since the rate of rifampicin attack on the RNA polymerase in RS
complex, k , is crucial in the determination of the rate of RNA chain
2
initiation, it must be assumed that k

2

is not affected by the presence
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of anthracyclines in order to use the rifampicin technique in the study
of the effect of anthracycline analogs on therateof RS to OP complex
transformation.
In ascertaining that anthracyclines have no effect on k , 42
demethoxydaunomycin and aclacinomycin were chosen to represent group I
and group II anthracyclines respectively.

Daunomycin was not chosen for

these experiments because it appears to interact with rifampicin, forming
a non-specific complex which is responsible for retaining radioactive
material on the filters thus giving erroneously high counts.
The assays used for determining the rate constants of rifampicin
inactivation of the RS complex in the presence and absence of the two
anthracycline analogs are described in the Methods (Section II.4.3.2.1.).
The results are presented in Figure lBa, b and c.
Under the assays conditions, where rifampicin is present in great
excess over RNA polymerase (over 10 fold), the kinetics for inactivation
of the enzyme in the binary complex by rifampicin are pseudo first-order,
as indicated by the first order rate plot in Figure 18.

In other words,

although the binding of rifampicin to RNA polymerase is a second-order
reaction, under conditions where the concentration of unbound antibiotic
can be considered constant during the reaction kobs
where k b
0

s

= k2

x [rifampicin],

is the apparent rate constant for the binding of rifampicin

to RNA polymerase and k

2

is the true second-order rate constant for the

reaction.
In the presence of 4-demethoxydaunomycin and aclacinomycin, RNA
polymerase in the enzyme-DNA binary complex has a half-life of approximately 3 minutes.

This half-life time is nearly identical with that
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Figure 18.

Kinetics of Inactivation of RNA Polymerase-T7 DNA Complex

by Rifampicin at 37° C

Enzyme-template binary complexes were formed by adding 1

~g

of

RNA polymerase in 10 pl of enzyme solution (Section II.4.3.) to a mixture
of 35 pl of buffer, 20 pl of DNA (170 pM) and 15 pl of H 0 or anthra2
cycline solution.

After 7 minutes of incubation, 10 pl of H 0 with or
2

without 0.38 pM of rifampicin was added.

Incubation was continued for

the indicated time intervals, then RNA synthesis was initiated by the
addition of 10 pl of 0.5 mM each of GTP, ATP, CTP and

3

H-labeled UTP.

The reaction was terminated 90 seconds later and the acid-insoluble
radioactivity was determined.
a) Incubation in rifampicin only; b) incubation in 9.9 pM
4-demethoxydaunomycin; c) incubation in 5.1 pM of aclacinomycin.
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obtained in the absence of anthracyclines and is in good agreement with
that reported by Hinkle under comparable conditions (Hinkle and Chamberlin, l972d).

This identical half-life for RNA polymerase under the in-

fluence of various anthracyclines indicates that the rate constant of
rifampicin attack on the enzyme in the RS complex is not affected by
either group I or group II anthracyclines.
The effect of different anthracycline analogs on the rate of RS
to OP complex transformation are shown in Figure l9a, and b.

For these

experiments the concentrations of anthracyclines were chosen so as to
cause 50% inhibition of RNA synthesis as determined in Section III.3.l.
From the comparison of the slopes of the plots of enzyme activity vs rifampicin concentration, it is evident that group II anthracyclines
show a striking difference in the way they affect the RS to OP transfermation as compared to group II anthracyclines.

Specifically, group II

anthracyclines exhibit basically identical slopes with the slopes obtained in their absence.

Since k

2

is not affected by the presence of

these drugs (Figure 18), this result indicates that the presence of
type II anthracyclines has no effect on the rate constant of RNA polymerase molecules which proceed from the RS complex to form the first
phosphodiester bond.

A similar conclusion has been drawn in a previous

study about the effect of Ethidium Bromide on the rate of RS to OP transformation (Aktipis and Panayotatos, 1977).
In contrast, group I anthracyclines produce an increase in the
k /k* (the slope) as compared to reactions in the absence of these drugs.
2
Since these drugs do not affect k

2

(Figure 18), it is clear that they

inhibit the rate of RS to OP complex transformation.

Other inhibitors

126

Figure 19.

The Effect of Anthracycline Analogs on the Rate of RNA

Synthesis Initiation

The rate of RNA chain initiation was measured as described in
Section II.4.3.2.2.

The DNA and RNA polymerase binary complexes were

incubated in the absence (e) and presence of anthracycline analogs at
37° C ( • , daunomycin;
0 , aclacinomycin;

~

, 4-demethoxydaunomycin;

• , marcellomycin;

o , carminomycin;

X, musettamycin).

RNA synthesis

was initiated with the subsequent simultaneous addition of rifampicin
and ribonucleotide substrates.

The reaction products were treated as

described in Section II.4.3.
The slope in this figure represents the ratio of the rate of
rifampicin attack on the RS complexes to the rate of RNA chain initiation,
k2/k*.
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which interfere with the RS to OP transformation do not appear to have
been reported in the literature.
III.3.4.2.2.

The Rate of I to RS Complex Transformation

Evidence has been presented (Mangel and Chamberlin, 1974a) that
RNA polymerase molecules bind to T7 DNA at or near the T7 early promoter
region in a conformation from which rapid RNA chain initiation is not
possible.

Enzyme molecules in this state (I complex) are in equilibrium

with enzyme molecules in the RS conformation from which rapid RNA chain
initiation can take place.

This equilibrium is temperature dependent;

formation of I complex is favored at low temperatures (lower than 10° C).
The isolation of I complex has lead to the conclusion that all E. coli
RNA polymerase molecules bind initially to T7 early promoter sites in
the I conformation in which the DNA helix remains in a double helical
state.

The enzyme molecules then carry out melting functions to separate

the strands and form the RS complex allowing enzyme the access to the
base pairing residues of the DNA template.

Therefore, this I to RS

complex transformation is an another essential step prior to the actual
initiation of an RNA chain.

This tranformation in the presence of anthra-

cyclines was studied in the following manner.
The effect of anthracycline analogs on the rate of I to RS complex transformation is shown in Figure 20 in which % RNA polymerase activity is plotted as a function of pre-incubation time of the I complex in
the presence and absence of rifampicin.

RNA polymerase % activity was

determined by dividing the radioactivity recovered either in the presence
of rifampicin or in the presence of both rifampicin and anthracyclines
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Figure 20.

The Effect of Anthracycline Analogs on the Rate of Transfor-

mation of I to RS Complexes

Binary Complexes between T7 DNA and RNA polymerase were formed
at 0° C in the absence ( 0) and presence (

~)

of anthracyclines.

The

reaction mixture was brought up to 37° C for the indicated pre-incubation
times before the addition of radioactive nucleotide substrate with or
without rifampicin.

The reaction was terminated 90 seconds later and

the product was processed as described in Section II.4.3.
The results are expressed as % RNA polymerase activity.
the ratio of RNA synthesized in the presence of rifampicin (0.156

This is
~g/ml)

only ( 0), or in the presence of both rifampicin and anthracycline ( ~),
over that when no rifampicin is present.
a) In the presence of 13.3
of 9.9

~M

~M

of daunomycin;

b) in the presence

of 4-demethoxydaunomycin; c) in the presence of 5.1

aclacinomycin.

~M

of
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with corresponding controls obtained in the absence of rifampicin.
I complex was formed by incubating RNA polymerase with T7 DNA
at 0° C under low salt condition either in the presence or the absence
of anthracyclines.
represent group I

Daunomycin and 4-demethoxydaunomycin were chosen to
anthracyclines

while aclacinomycin was chosen to

represent group II anthracyclines.
As can be seen from Figure 20, for the first 60

seconds the

amount of I complex which can be transformed into RS complex and escape
the attack of rifampicin increases rapidly as the pre-incubation time
increases.

Beyond this initial surge, the increase of radioactivity in-

corporated slows down rapidly and reaches a plateau at around 3 minutes.
The half-life time for the I complex in the presence and absence
of anthracyclines can be obtained by plotting the percent of RNA polymerase activity at infinite pre-incubation time (too) minus the RNA
polymerase activity at time (t) on a logarithmic scale against preincubation time.

The results are presented in Figure 21 which shows sim-

ilar half-lives for all the anthracyclines tested, indicating that anthracyclines exert no significant effect on the rate of I to RS complex
transformation.

III.3.4.2.3.

The Effect of Anthracyclines on the Transition Temperature
of I to RS Complex Transformation

It has been reported that the equilibrium between the I and RS
complexes is altered by temperature in a manner characteristic of a highly cooperative process (Mangel and Chamberlin, 1974a).

An enthalpy of 57

Kcal per mole has been calculated for the formation of RS complex with
T7 DNA and a transition temperature of 18° C has been determined.
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Figure 21.

Half-life of the Transformation of the I to RS Complex

Binary complexes between T7 DNA and RNA polymerase were formed
at

oo

C in the absence ( 0 ) and presence of 13.3 pM of daunomycin (

~

);

9.9 pM of 4-demethoxydaunomycin ( • ) , and 5.1 pM of aclacinomycin( 0
respectively.

The reaction mixture was then brought to 37° C for the

indicated pre-incubation times before initiation.

The reaction was stop-

ped 90 seconds later and the product was processed as described in
Section II. 4. 3.
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If the rate of I to RS complex transformation is indeed not
altered by the presence of anthracyclines as concluded from previous
experiments, then the temperature dependency of the rate constant should
not be affected by the drugs either.

This temperature dependency could

be studied by determining the transition temperatures of I to RS complex
transformation in the presence of anthracycline analogs.
In this experiment, a constant amount of T7 DNA was mixed at 0° C
with RNA polymerase in the presence and absence of daunomycin and aclacinomycin, representing group I and II anthracyclines respectively.

The

I complexes formed were then pre-incubated at various temperatures for 7
minutes before being challenged with rifampicin and substrates at 37° C.
The results are presented in Figure 22 in which the % RNA polymerase
activity in the presence and absence of each anthracycline is plotted vs
pre-incubation temperatures.

As expected, the transition temperature of

approximately 18° C remains unchanged regardless of whether or not intercalators are present.

This transition temperature is in close agreement

with that reported previously by Mangel (Mangel and Chamberlin, l974a).
The nearly identical transition temperatures irregardless of the presence
or absence of anthracyclines provides an independent confirmation of the
previous conclusion that
complex transformation.

anthracyclines have little effect on I to RS
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Figure 22.

The Effect of Anthracycline Analogs on the Transition Temper-

ature of I to RS Complex Transformation

Binary complexes were formed between T7 DNA and RNA polymerase
at various temperatures in the absence or presence of anthracyclines
representing each group.

The reaction mixture was then incubated at the

indicated temperatures for 7 minutes before initiation at 37° C.

The

results are expressed as % RNA polymerase activity which is the ratio of
the amount of RNA synthesized in the absence of anthracycline (

e )

but

in presence of rifampicin over that in the absence of both anthracycline
and rifampicin.

The same experiment was repeated in the presence of

daunomycin (13.3

~M,

0) and aclacinomycin (5.1

~M,

• ).
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III.3.4.3.

Comparison of the overall RNA synthesis inhibition and the
inhibition of RNA chain initiation by anthracyclines

The inhibitory effectiveness of daunomycin and aclacinomycin towards RNA chain initiation was also examined by assaying the simultaneous
1ncorporat1on o f 32 P-ATP an d 3 H-UTP ( Sec t 1on II . 4 . 3 . 1 . ) .
0

0

l- 3 4?-ATP

0

The amount of

incorporated indicates the number of RNA chains that can be

initated in the presence of the drugs while the amount of 3H incorporated
measures the rate of overall RNA synthesis.

In Figure 23 the amount of

RNA synthesized in terms of the RNA polymerase activity is plotted
versus the added drug to DNA ratio for daunomycin and aclacinomycin.
It may be noted that the overall inhibition of RNA synthesis by
daunomycin is much stronger than the inhibition of the number of RNA
chains that can be initiated.

Since l-32P incorporation measures the

events of RNA initiation up to the formation of the first phosphodiester
bond, the difference seen between

32

P and

3

H incorporation can only be

attributed to the subsequent inhibition of RNA chain elongation.

There-

fore at drug to DNA ratio of 0.175 at least 17% of the overall inhibition
of RNA synthesis by daunomycin is due to the inhibitory effect of the
drug on chain elongation.

Aclacinomycin, on the other hand, does not

affect chain elongation as indicated by the fact that the inhibition of
the overall RNA synthesis coincides with the inhibition of the chain initiation.
The data obtained from the filter binding assay (which measures
the amount of RNA polymerase-DNA complex formed in the presence of anthracyclines) and the data of 32 P an d 3 H 1ncorporat1on are expresse d 1n terms
0

0

0

of rb (the number of drug molecules bound per DNA phosphate) a shown in
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Figure 23.

Inhibition of RNA synthesis by daunomycin and aclacinomycin

assayed by the simultaneous incorporation of

32

P-ATP and

3

H-UTP

RNA polymerase and T7 DNA complexes were formed at 37° C in the
presence of various amountsof daunomycin and aclacinomycin.

RNA syn-

thesis was then initiated by the rapid addition of nucleoside triphosphate mixture containing
activities: 1

~Ci/nmol

r-

32
3
P-ATP, CTP, GTP and 5,6- H-UTP (specific

and 0.02 pCi/nmol, respectively) at a concen-

tration of 5 mM for each nucleoside triphosphate.
The amount of RNA synthesized in the presence of daunomycin in
terms of

32
3
H (e) or
P ( 0) incorporation, or in the presence of acla-

cinomycin in terms of

32
3
H (A) or
P ( 6) incorporation, is expressed

as% RNApolymerase activity versus the added drug to DNA ratio.
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Figure 24.

These data indicate that under the influence of aclacinomycin

the level of RNA polymerase-DNA complex formation, the level of overall
RNA synthesis and the level of RNA chain initiation all closely follow
each other.

This however is not the case for daunomycin.

It is clear

that the inhibitory effect of aclacinomycin on RNA synthesis can be
totally explained by its effect on the binding of the enzyme to DNA.
other step in the RNA synthesis process is affected by this drug.
daunomycin, the situation is more complicated.

No

For

At an rb of 0.015 a 13%

difference between the inhibition of the formation of the complex and the
inhibition of the RNA chains is noted.

This effect is attributed to

daunomycin inhibition of the RS to OP complex transformation, i.e., inhibition of the rate of the formation of the first phosphodiester bond.
However, there is also an additional 17% difference between the inhibition of the overall RNA synthesis and the inhibition of the initiation of
the RNA chains.

This difference can only be attributed to the inhibition

of RNA chain elongation.
The overall inhibition of RNA synthesis by daunomycin may be divided into two main categories; 1) the inhibition of enzyme-DNA complex
formation and 2) the inhibition of the rate of RNA synthesis which includes the inhibition of RS to OP complex transformation and elongation.
The relative amount of inhibition of the rate of RNA synthesis attributable to either the inhibition of RS to OP complex transformation or the
inhibition of chain elongation is dependent on the concentration of daunomycin.

At rb

= 0.009,

17% of the rate inhibition is due to the inhibition

of RS to OP complex transformation while 83% is due to inhibition of
elongation.

At rb

= 0.013,

27% and 73% of rate inhibition is due to in-

144

Figure 24.

Compositeplotof% RNA polymerase activity and% of I

complex formation in the presence of daunomycin and aclacinomycin

The% RNApolymerase activity in the presence of daunomycin in
terms of

3
H

( • ) or 32 P ( 0 ) incorporation and the % of enzyme-DNA

complex formation ( O ) are plotted versus rb (the number of drug molecules bound per unit DNA).
aclacinomycin in terms of

The same plots are also constructed for
3
H ( •

),

32

of enzyme-DNA complex formation ( • ).
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hibition of RS to OP complex transformation and elongation, respectively.
The inhibition of RS to OP complex transformation relative to the inhibition of elongation increases further at even higher rb values (i.e.,
at rb

=

0.015 which causes 43% and 57% for inhibition of complex trans-

formation and elongation, respectively).

This observation indicates that

at high daunomycin concentration, the inhibition of RS to OP complex
transformation becomes more significant.

A similar effect may have also

been noted previously from the studies of Miracil D

(Bodoni, 1978).

this report Miracil D was found to inhibit the initiation at high rb
values in addition to its inhibitory effect on elongation but at lower
rb values Miracil D was found to inhibit only elongation.

In

CHAPTER IV

DISCUSSION

The anthracycline analogs examined in this study can be divided
into two groups according to their structural characteristics.
tural differences between anthracyclines in group I

The struc-

(daunomycin, 4-deme-

thoxydaunomycin and carminomycin) and group II (aclacinomycin, marcellomycin and musettamycin) anthracyclines are shown in Figure 1 and are discussed in Section I.4.

The major differences relate to the nature of the

substituents at C-10 and C-13 of the aglycone and the nature of the glycosidic side chain.

These structural differences have been shown in

this study to influence not only the binding affinities of these drugs
to DNA but also the mechanism by which they inhibit RNA synthesis in
vitro.
RNA synthesis was studied at an RNA polymerase to DNA molar ratio
of 12 which ensured that only the major promoter sites on DNA template
were utilized (Figure 10, Section III.2.).

Under this condition, both

daunomycin and aclacinomycin were found to inhibit the in vitro DNAdependent RNA polymerase activity competitively (Fig. 16, Section III.3.2.)
at DNA concentration which corresponded to maximum incorporation of radioactive substrate (Fig. 12, Section III.2.).

This competitive mode of

inhibition of RNA polymerase by anthracyclines is consistent with the
proposal (Section I.2.8.1.) that the inhibition of RNA polymerase activity by anthracyclines is primarily due to the inactivation of the DNA ternplate.

This conclusion is also supported by the observation that pre-

incubation of RNA polymerase with the inhibitors has no effect on the
147
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level of RNA synthesis (Section III.3.2.).
It has been proposed that the inhibition of RNA polymerase by
anthracyclines results from intercalation (Section I.2.7.2.).

However,

the precise mechanism by which the intercalators inhibit the template
activity of DNA remains unclear.

In this investigation, it has been

shown that all the anthracycline analogs examined reduce substantially
the binding of RNA polymerase at the major promoter sites of T7 DNA
(Fig. 17, Section III.3.4.1.).

It is likely that RNA polymerase is pre-

vented from binding to the template because the enzyme binding sites are
already occupied by the intercalators, or due to steric hindrance by the
molecules of the bound drug in the vicinity of the enzyme binding site.
There are substantial differences in the effectiveness of group I
and II anthracyclines as inhibitors for the formation of the enzymetemplate binary complex.

Specifically, the drug to DNA ratios which

causes 50% reduction in the formation of the enzyme-template binary complex are approximately 0.09 and 0.04 for group I and II anthracyclines
respectively (Table IV, Section 3.4.1.), indicating that group II drugs
are at least twice as effective in inhibiting the formation of the enzymetemplate binary complex than group I drugs.
The differences in the binding abilities between group I and II
anthracyclines to DNA have been attributed to several major structural
differences between these drugs.

Specifically, the additional sugar

residues on the glycosidic side chain and the presence of a C-10 carbomethoxy substituent in group II anthracyclines increases the binding
affinities of anthracyclines to DNA (DuVernay et al., 1979a), while the
presence of a substituted amino group on the primary sugar significantly
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reduces binding (DuVernay et al., 1979b).

The enhanced binding of group

II anthracyclines to DNA, in terms of both the association constant and
the number of binding sites per unit DNA, is evident under the conditions
employed in the present study (Table I, Section III.l.).

It appears that

both the carbomethoxy residue and the additional sugar residue of group
II anthracyclines are involved in increasing the stability of the intercalated complex to an extent which compensates for the loss of binding
due to the presence of substituted amino groups.

It is likely that the

carbomethoxy component and the additional sugar residues offer greater
opportunity for additional hydrogen bonding and better Vander Waals interactions between the intercalators and the DNA template.

However, group II

anthracyclines also lack a carbonyl group at position C-13 which has been
claimed to be involved in a hydrogen bonding with DNA to further stabilize the intercalated complex (Section I.2.7.3.).

Lack of this hydrogen

bond may seriously compromise the stability of the complex formed by
group II anthracyclines.

This may explain the observation that when the

ability to bind DNA and prevent the formation of enzyme-DNA complex is
compared between daunomycin (group I) and aclacinomycin (group II) in
terms of rb (the number of drug molecules bound per unit DNA), group I
drugs become just as effective as group II drugs (Fig. 24, Section, III.
3.4.3.).

This observation indicates that each DNA-bound molecule of

daunomycin is just as effective in preventing the formation of complex
as is each molecule of aclacinomycin.

The difference between the two

drugs seen in terms of their added drug to DNA ratio may be attributed
to the fact that the number of binding sites for group II drugs are
greater than that for group I drugs.

Therefore, when the same concentra-
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tion of daunomycin or aclacinomycin is added to the DNA more molecules
of group II anthracyclines can bind to DNA and thus prevent the formation
of enzyme-DNA complex to a higher extent.

The differences in the binding

constants of these anthracyclines to DNA seem to play a minor role in
determining their effectiveness as inhibitors toward the formation of the
enzyme-DNA complex.
Since the binding of RNA polymerase to DNA at major promoter sites
leads to the formation of an enzyme-template binary complex which is a
necessary for the subsequent events in specific RNA synthesis initiation
(Section I.3.4.), it may be proposed that the reduction in the formation
of this enzyme-template binary complex by anthracyclines accounts for
the resulting inhibition of RNA synthesis.

However, when the effective-

ness of anthracyclines in reducing enzyme-template complex formation
(Fig. 17 and Table IV, Section III.3.4.1.) is compared with the effectiveness of these drugs as inhibitors of RNA synthesis (Fig. 14 and
Table II, Section III.l.), some interesting discrepancies become apparent.
While it is clear that the extent of enzyme-template complex inhibition
by group II anthracyclines parallels the extent of RNA synthesis inhibition, i.e., the drug to DNA ratio which causes 50% of inhibition in
both the process of complex formation as well as RNA synthesis is similar
for group II antibiotics (e.g., 0.033 for marcellomycin), this is not the
case for group I anthracyclines.

From the same comparison for group I

drugs it becomes evident that a higher drug concentration is required
(for example, 4-demethoxydaunomycin at a ratio of 0.058 prevents the
synthesis of RNA by 50% whereas in order to prevent the formation of the
binary enzyme-template complex to the same extent 4-demethoxydaunomycin
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must be present at a much higher ratio, i.e., 0.085) so that the formation of binary complex can be inhibited to the same extent as the
synthesis of RNA.

In other words, RNA synthesis inhibition by group I

anthracyclines can be explained only partially by the effect of these
drugs on binary complex formation.

Therefore the differential inhibitory

capacity of the anthracyclines is not simply the result of their different
affinities for DNA for group I anthracyclines.

Other factors must also

be involved in the mechanism of the inhibition of RNA synthesis.
The study of interactions between DNA and drugs is not a simple
task because DNA contains multiple binding sites for drug molecules (Table
I, Section III.l.).

The structures of the drugs also influence the

strength of the binding (Table I).

Since anthracyclines inhibit the

synthesis of RNA by reducing the availability of DNA template sites for
the binding of RNA polymerase, the form of the drug in solutions which
behaves as an inhibitor is the DNA-bound form.

The appropriate means of

expressing quantitatively the concentration of DNA-bound drug is in terms
of the ratio of drug molecules bound per DNA nucleotide, (rb)
III.3.3.).

(Section

Since rb does not depend linearly on the total drug concen-

tration (Section III.3.3.), the availability of rb values is essential
for the comparative study of the inhibitory effectiveness of anthracycline analogs which have different affinities toward the DNA template.
When the dependence of RNA polymerase activity was determined
as a function of rb for each drug (Fig. 15, Section III.3.3.), a different
picture for the relative effectiveness of the various anthracyclines
studied became apparent.

Specifically, group I anthracyclines are more

effective inhibitors of RNA synthesis than group II drugs.

These results
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also indicate that identical numbers of bound inhibitor molecules per
molecule of DNA have different inhibitory effects on the activity of
RNA polymerase.

Consequently, the inhibitory effectiveness of group I

anthracyclines is determined not only by the affinity of each compound
towards DNA, as in the case with group II anthracyclines, but also by
the specific structures of the intercalated molecules.
What is the basis for the differential inhibitory effect on RNA
synthesis between group I and II anthracyclines?

An answer to this

question can be found by comparing the rates of transformation of the
binary enzyme-DNA complex during the events leading to the initiation of
RNA synthesis in the presence of group I and II inhibitors.
E. coli RNA polymerase molecules bind to T7 DNA at or near promoter sites to form I complex (Section I.3.4.).

I complexes are then

transformed through an energy requiring step involving the separation
of the double helical strands of DNA to form RS complexes.

In the pre-

sence of nucleoside triphosphate substrates, the RS complexes can be
transformed to OP complexes with the formation of the first phosphodiester
bond.

The rates of I to RS and RS to OP transformation can be measured

(Section III.3.4.2.).
In the present study the effect of anthracyclines on the rates of
these transformations was examined.

The results clearly indicate that

in the presence of group II anthracyclines, the number of RS complexes
is reduced (Fig. 17, Section III.3.4.1.) but the rate of RS to OP complex
transformation is not affected (Fig. 19, Section III.3.4.2.1.).

The

reduced number of RS complex could be the consequence of either a reduced
number of I complexes or a reduced rate of I to RS transformation, or it
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may be the result of both.

Since I complexes in the process of their

transformation to RS complexes are not affected by the presence of
group II anthracyclines (Fig. 20-22, Section III.3.4.2.2.), the only
explanation for the reduced number of RS complexes that can be offered
is that the number of I complexes is substantially reduced by group II
anthracyclines.

This observation leads to the conclusion that inhibition

of RNA synthesis by group II anthracyclines is entirely due to the effect
of these drugs in preventing the formation of enzyme-template binary complex.

This conclusion is also consistent with the findings (Fig. 24,

Section III.3.4.3.) that the extent of enzyme-DNA complex inhibition,
the extent of inhibition of RNA initiation (RS to OP complex transformation) and the extent of inhibition of overall RNA synthesis are all
identical in the presence of aclacinomycin (a group II anthracycline).
On the contrary, group I anthracyclines reduce the number of RS
complexes (Fig. 17, Section III.3.4.1.) as well as the rate of RS to OP
transformation (Fig. 19, Section III.3.4.2.l.) but they do not affect
the rate of I toRS transformation (Fig. 20-22, Section III.3.4.2.2-3.).
By the same analogy described above for group II drugs, it seems that
group I anthracyclines also reduce the number of I complexes.

In addi-

tion, however, once I complexes have proceeded to become RS complexes,
the subsequent RS to OP transformation is also affected by group I anthracyclines, probably due to the interference of these drugs with the formation of the first phosphodiester bond.

(At this point it should be noted

that the effect of daunomycin on RS to OP complex transformation is not
an artifact due to its inhibition on chain elongation.

Miracil D, which

has been shown to be a chain elongation inhibitor at low drug concentra-
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tion, has no effect on the rate of RS to OP transformation when measured
in an identical assay utilizing rifampicin (data not shown).
Finally, a comparison of theratesof initiation of RNA chains
and overall RNA synthesis (Fig. 23, Section III.3.4.3.) shows that
daunomycin (group I anthracycline) also inhibits the elongation of RNA
chains.

Furthermore, the relative amount of RNA synthesis inhibition by

daunomycin due to either the inhibition of the RS to OP complex transformation or of the elongation of RNA chains is dependent on the concentration of the drug (Section III.3.4.3.).

At high drug concentration the

inhibition of RS to OP transformation becomes more significant.

These

additional steps of inhibition explain the observation cited previously
that inhibition of the enzyme-template complex by group I anthracyclines
can only partially account for the inhibition of RNA synthesis.
Numerous attempts have been made (Section I.4.) to establish a
relationship
properties.

between the structures of anthracycline analogs and their
It is quite apparent from the results of this study that

the structural differences between group I and II

anthracyclin~s

contri-

bute to the differences in the tendencies of the members of the two
groups to bind DNA.

The latter property directly affects the effective-

ness of anthracyclines as inhibitors of RNA synthesis.

More specifically,

the structural differences among these drugs appears to affect the mechanism of initiation of RNA synthesis, i.e., the various members of group
I anthracyclines affect RS to OP transformation and elongation, while
group II anthracyclines do not.
It has been established that the amino group on the sugar residue
of daunomycin is positively charged at neutral pH.

This charged amino
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group plays an important role in the formation of a stable intercalated
complex between daunomycin and DNA (DiMarco. et al., 1971) by having
electrostatic interaction with the negatively charged phosphate backbone
of DNA.

Alteration of this amino group (either by elimination or sub-

stitution) may result in a significant reduction of intercalation.

It

has also been proposed that at very high drug concentration, this positively charged amino group is responsible for the secondary binding of
the drug with the phosphate backbone of the DNA helix.

In this case,

drug molecules, rather than intercalating into DNA, are located on the
outside of the double helix (Section I.2.7.2.).

This secondary binding

takes place presumably after the intercalation sites have been saturated
at high drug concentration.
In the present study, the potential for secondary binding for
group I anthracyclines is evident from the Scatchard plots (Fig. 9a,
Section III.l.) at very high drug concentrations.

This finding is con-

sistent with the presence of an unsubstituted amino group on the primary
sugar residue.

Group II anthracyclines carry a substituted amino group

and do not form secondary binding as is evident from the linearity of
the corresponding Scatchard plots (Fig. 9b, Section III.l.).

However,

since the assays for the inhibition of RNA synthesis by anthracyclines
were carried out at drug concentrations far below (below rb = 0.035, Fig.
15) the level at which secondary binding takes place (above rb

= 0.05,

Fig. 9a), any differences seen between the mechanisms of RNA synthesis
(e.g. RS to OP transformation) by group I and group II drugs cannot be
attributed to secondary binding.
A possible cause for the additional step of inhibition of RS to OP
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transformation by group I drugs then, is the presence of electrostatic
interaction between their amino groups and the phosphate backbone of
DNA in the intercalated complex.

This electrostatic interaction may

impair the catalytic function of the RNA polymerase by interfering at
the catalytic site in a manner which inhibits the formation of the first
phosphodiester bond.

The same electrostatic interaction within the

intercalated complex may also retard the rate of elongation.
In contrast, group II anthracyclines, which do not carry a positively charged amino group and are therefore unable to interact electrostatically with DNA phosphate, apparently interfere only with the formation of I complexes and have no effect on the formation of the first
phosphodiester bond.
The results presented in this dissertation suggests that the
unsubstituted amino group on the primary sugar residue of anthracyclines
may play an imporant role in determining the mechanism by which anthracyclines inhibit RNA synthesis.

Both group I and group II anthracyclines

inhibit RNA synthesis by interfering with the formation of a specific
template-RNA polymerase binary complex (I complex).

However, in addition

to inhibiting the formation of the I complex, group I anthracyclines interfere with the transformation of the rapidly starting complex (RS
complex) to the OP complex, (i.e., a complex containing the first
phosphodiester bond of the nacent RNA chain) and with the elongation of
RNA chains.

CHAPTER V

SUMMARY
The in vitro synthesis of RNA catalyzed by E. coli DNA-dependent
RNA polymerase using T7 DNA as template is inhibited by anthracycline
analogs.
The initiation step of RNA synthesis is a multi-step process involving 1) the binding of the enzyme molecules to the non-specific binding sites on the template, 2) the binding of the enzyme molecules to
major promoters to form I complex, 3) the melting of the double-stranded
DNA at enzyme binding site to form RS complex and 4) the formation of the
first phosphodiester bond.
Anthracyclines apparently inhibit RNA synthesis by intercalating
into DNA double helix and interfering with template function.

In the pre-

sent study two groups of anthracyclines which differ in the substituents
at C-10 of the aglycone and the amino group of the primary sugar moiety,
were examined to determine their relative effectiveness in binding to DNA
and in inhibiting the synthesis of RNA.
When identical amounts of anthracycline from each group are added
to DNA, group II anthracyclines (which carry a carbomethoxy group at C-10
and a substituted amino group on the sugar moiety) inhibit overall RNA
synthesis to a greater extent than group I drugs.

This higher inhibitory

effectiveness of group II anthracyclines towards overall RNA synthesis is
the result of their better binding for DNA.

However, when comparisons are

made with the same number of molecules from each group of anthracyclines
bound to DNA, group I anthracyclines show a higher effectiveness as inhi157
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bitors of RNA synthesis.

This enhanced inhibitor activity is attributed

to a distinctive feature in the mechanism by which group I anthracyclines
inhibit RNA synthesis.

Group I anthracyclines reduce not only the number

of I complexes that can be formed, but also the rate of transformation of
these complexes from RS to OP form as well as the rate of RNA chain elongation.

In contrast, group II anthracyclines act only by limiting the

number of I complexes.
In conclusion, it appears that group I anthracyclines inhibit the
formation of I complex through intercalation and the rate of RS to OP
transformation and RNA chain elongation through electrostatic interactions
within the intercalated complex, thus acting as multiple inhibitors.

In

contrast, group II anthracyclines, which carry substituted amino groups,
and are thus unable to form similar ionic interactions, inhibit, as a
result of intercalation, only the formation of I complex.
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